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SUMMARY
+
(1) Regulation of NA release from rat O.C. tissue chops is K and
2+
Ca dependent.
+ 3
(2) K -stimulated release of [ H]NA from rat O.C. and
hypothalamic tissue chops is inhibited by a -adrenergic
the inhibitory effect is
agonists and^reversed by oc -adrenergic antagonists.
+ 3
(3) In O.C. tissue chops, 20mM K -stimulated release of [ HJNA
is enhanced by db-cAMP, forskolin and IBMX but inhibited by
RO 20-1724. In addition, db-cAMP or forskolin when combined
+
with IBMX further enhanced the K -stimulated release of 
3
[ H]NA while the inhibitory effect of RO 20-1724 on
+ 3
K -stimulated release of [ H]NA is reversed by db-cAMP or
forskolin. The 0C2~a^rener<3i-c agonist inhibition of
+ 3
K -stimulated release of [ H]NA is partially reversed by
db-cAMP alone but not by forskolin.
(4) In hypothalamic tissue chops, 25mM, but not 30mM,
+ 3
K -stimulated release of [ H]NA is enhanced by db-cAMP or
forskolin combined with IBMX. However, the inhibitory effect
+ 3
of clonidine on K -stimulated release of [ HJNA is not
reversed by either db-cAMP or forskolin in the presence of IBMX,
6
(5) The selective adenosine A^ agonist, N -cyclohexyl adenosine
+ 3
(CHA) inhibited 20mM K -stimulated release of [ HJNA from
O.C. tissue chops more potently than adenosine. The inhibitory 
effect of adenosine is reversed by IBMX but not by RO 20-1724.
- xiii -
-4
Furthermore, IBMX (10 M) is not only able to reverse the
+ 3
adenosine inhibition of K -stimulated release of [ H]NA, but
3
also enhances the release of [ H]NA to approximately 20%.
Also, the selective adenosine antagonist
-5
8-cyclopentyl-l,3-dopropylxanthine (CPDPX) (10 M) not only
+
reverses the adenosine inhibition of K -stimulated release of
3 3
[ H]NA but further enhances the release of [ H]NA by about
10%.
(6) Direct measurement of intracellular cAMP formation by the method
of Shimizu et al. (1969) showed that the ^-adrenergic agonist,
+
isoprenaline,as well as NA, adenosine, forskolin and K all 
stimulated cAMP formation maximally by about 1.5, 3.0, 3.5, 7 
and 2.5 fold repesctively.
(7) Isoprenaline stimulation of cAMP formation is potentiated by 
the OC^-adrenergic agonist, phenylephrine, but not affected by 
the OC^-adrenergic agpnist, UK 14304-18.
(8) NA stimulation of cAMP formation is not affected by
phenylephrine, but partially inhibited by (^-adrenergic 
agonists in a biphasic manner with the following order of
potency (IC^ values in parenthesis) UK 14304-18 (6 x
-9 -8 -7
10 M) >  clonidine (10 M) >  BHT-920 (5 x 10 M).
However, there is no evidence that a 2~a^rener9^c agonists
+
inhibit the isoprenaline, forskolin and K -stimulation of cAMP 
formation.
- xiv -
(10)
(11)
a-and j3-Adrenergic antagonists inhibit NA stimulation of cAMP
formation with the following order of potency, propranolol ( )>
prazosin (a ) = yohimbine (a ) and with IC values of 
1 2 50
-9 -8 -8
6 x 10 M, 3 x 10 M and 3 x 10 M respectively.
+
Isoprenaline, NA, adenosine and 20mM K stimulation of cAMP 
formation is blocked by IBMX, but not by RO 20-1724. In 
contrast, forskolin stimulation of cAMP formation is not 
affected by either IBMX or RO 20-1724.
Adenosine stimulation of cAMP formation is potentiated by NA and 
UK 14304-18.
(12) These results are discussed in relation to current hypotheses on 
the mechanisms by which a^-adrenergic agonists modulate NA 
release in the CNS.
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1. INTRODUCTION
1.1 Neurotransmitters
Neurotransmitters are chemical compounds found in the nerve 
terminals of neurons which are released into the synapse in response to 
nerve impulses (Katz and Miledi, 1969) or membrane depolarization 
(Schoffelmeer et al., 1981). Examples of neurotransmitters identified 
in the brain include catecholamines (noradrenaline and dopamine), amino 
acids [glutamate, y  -aminobutyric acid (GABA) and aspartate], 
acetylcholine, histamine, serotonin (see Chesselet, 1984; Middlemiss, 
1988, for review) and several neuropeptides including methionine or 
leucine eukephalin, endorphins, substance P, neurotensin, 
cholecystokinin (Bradford, 1986b).
Neurotransmitters play a very important role in neuroscience as 
they provide the basic link between neurons. Thus, many biological and 
physiological changes are affected by the release of neurotransmitter.
A few examples are (a) high concentrations of NA cause hypertension (De 
Champlain et al., 1967; Przuntek et al., 1971), (b) dopamine deficiency 
leads to mental deterioration in Parkinson's disease (Lees and Smith, 
1983) and (c) loss of cholinergic neurons in the brain lead to senile 
dementia, or Alzheimer's disease (Robbins, 1988). Furthermore, 
deficits in the noradrenergic system have been reported in postmortem 
Alzheimer brains. This involves the decrease of both noradrenaline 
(Aldolfsson et al., 1979) and dopamine- ^ -hydroxylase levels (Cross 
et al., 1981), particularly in the cortex and hypothalamus. Thus, the 
study of the regulation of neurotransmitter release may lead to more 
understanding on neuronal functions that may indirectly control our 
biological responses.
- 2 -
1.1.1 Criteria identification of a neurotransmitter
A number of criteria have been suggested which a compound has to 
fulfil before it can be classified as a neurotransmitter. When a 
chemical compound fulfils most but not all the requirements for a 
neurotransmitter, it is then known only as a putative neurotransmitter.
(1) The chemical compound must be stored in those neurons from which 
it is released.
(2) Precursors for the biosynthesis of the chemical compound must be
present.
(3) Enzymes necessary for the synthesis of the chemical compound
must be present in the same neurons.
2+
(4) Ca dependent release of the chemical compound to the 
extracellular fluids upon nerve stimulations.
(5) Mechanisms e.g. active uptake into nerve ending, must be present 
for the inactivation of the released chemical compound.
(6) Specific neuroreceptors for the chemical compound must be 
present at both pre- and post-synaptic sites.
(7) It must be able to recognise the specific pharmacological 
agents, such as agonists or antagonists at its receptor sites. 
Drugs used must be able to mimic the response of the chemical 
compounds at the synaptic sites.
The above statements can be depicted diagrammatically as in 
Figure 1.
1.2 Catecholamines
Catecholamines are compounds with amines attached to a benzene 
ring bearing two o-phenolic hydroxy groups (Catechol). Examples of 
naturally occurring catecholamines are dopamine [ ^ (3,4-dihydroxyphenyl)
- 3 -
Nerve terminal
Precursors
(a)
SynthesisNerve
activation
Neurotransmitter
(NT)
Change in
membrane
potentiation
Storage
Vesicles Presynaptic
neuron
release
Glial
cell
Uptake and 
inactivation
Postsynaptic
neuron
Figure 1 Basic principle of neurotransmitters at synaptic sites.
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ethyl amine], Noradrenaline (Norepinephrine), and Adrenaline 
(Ephinephrine). Their structural formulae are depicted in Figure 2.
The main sites of production of catecholamines are the brain, the 
sympathetic neurons and the chromaffin cells of the adrenal medulla. 
However, the most important catecholaminei-- neurotransmitters produced in 
the brain are dopamine and noradrenaline, while epinephrine is mainly 
produced quantitatively by the chromaffin cells of the adrenal medulla.
1.2.1 Noradrenergic pathways
The neuroautomical distribution of noradrenaline was detected by 
the use of formaldehyde histofluroescence technique (Falk et al., 1962; 
Fuxe, 1965). The noradrenergic pathways were distinguished by the 
fluroescence colours given by the aldehyde derivatives of noradrenaline. 
The use of high performance liquid chromatography with electrochemical 
detection (HPLC-ED), which is a highly selective and sensitive method of 
measuring ' catecholamines down to pico mole amounts helped to confirm 
the histochemical results as it allowed the same degree of precision in 
the localization of catecholaminergic pathways (Keller et al., 1976; 
Felice et al., 1978; Westerink and Mulder, 1981).
Noradrenaline nerve terminals in the cerebellum, hypothalamus, 
hippocampus and cerebral cortex arise from the perikarya in the lower 
brain stem, most notably the locus coeruleus as depicted in Figure 3.
1.2.2 Biosynthesis of catecholamines
Tyrosine was shown to be the direct precursor for catecholamine 
biosynthesis in the in vivo and in vitro study using radiolabelled 
tyrosine (Clonet et al., 1970; Harris and Roth, 1970; Heffner et al., 
1980; Bennett et al., 1981). The biosynthetic pathway for 
catecholamines is as shown in Figure 4.
- 5 -
h o y ^H(A^
Catechol (dlhydroxybenzene)
a
H0' h ^ V CH2-CH2-NH2
i  4
Dopamine [p(3^4-dIhydroxypheynl) 
ethyl amine]
C— C— NH
CH. H" H
C— C— N
H H CH3
Noradrenaline (Norepinephine) Adrenaline (Epinephlne)
Figure 2 Structural formulae of catecholamines
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Cerebral cortex Hippocampus Cerebellum
Median forbrain 
bundle Hypothalamus Locus coeruleus
Stria medullaris
Figure 3 Noradrenaline pathways in rat brain shown in sagittal
section
Hatched areas represent nerve terminal fields. Pathways descending 
to the cerebellum and brain stem nuclei are not shown (From 
Ungerstedt, U. (1971) Acta Physiol. Scand. Suppl. 367, 49-67).
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Tyrosine is converted to 3,4-dihydroxyphenylalanine (dopa) by
the enzyme Tyrosine hydroxylase (Tyrosine-3-mono-oxygenase, EC 1.14*6.2)
2+
which uses tetrahydrobiopterine, molecular C^, Fe and NADPH as its
cofactors. Tyrosine hydroxylase is considered to be the rate-limiting
step for dopamine and noradrenaline synthesis, since the enzyme reaction
is the slowest of the sequence (Bradford, 1986). Catecholamine
depletion is observed when tyrosine hydroxylase is inhibited by drugs
like a-methyl para-tyrosine (a-MpT) (Iversen and Glowinski, 1966;
Bennett et al., 1981). cAMP-mediated phosphorylation may lead to the
activation of tyrosine hydroxylase, thereby increasing its afinity for
the pteridine cofactor for tyrosine (Mestikawy and Glowinski, 1983).
2+ +
Increase in the conductance of Ca either by K -depolarization of 
neuronal membrane potential (Harris and Roth, 1970) or via the 
regulation of cAMP dependent protein kinase may also affect the tyrosine 
hydroxylase activity (Harris and Roth, 1970). When the noradrenergic 
vesicles are filled with noradrenaline, further synthesis of 
noradrenaline is inhibited. This is because excess NA competes with 
pteridine cofactors for the tyrosine hydroxylase, thereby decreasing the 
enzyme activity (Harris and Roth, 1970). Feedback inhibition of 
dopamine, synthesis is also observed in dopaminergic neurons (McGeer 
et al., 1967).
In both the noradrenergic and dopaminergic neurons, dopa is then
decarboxylated by the enzyme dopa-decarboxylase which uses pyridoxal
phosphate as its cofactor to convert it to dopamine. However in
noradrenergic neurons the enzyme dopamine-^ -hydroxylase, using
2+
ascorbate, molecular C>2 and Ca as its cofactors will then covert 
dopamine to noradrenaline.
For a small group of neurons in the brain stem and chromaffin 
cells of adrenal medulla, NA is further converted to adrenaline by the
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enzyme phenylethalamine N-methyl transferase (PNMT). The enzyme uses
S-adenosylmethionine as its cofactor. Surprisingly, the PNMT exists in 
a soluble cytosol outside the catecholamine storage vesicles. The
level of PNMT can also be regulated by corticoisteroids.
1.2.3 Receptors for Noradrenaline
Based on the various physiological studies on the relative 
potency of agonists, Alquist (1948) proposed that there were two types 
of catecholamine receptors, which he termed a - and p -adrenoceptors. 
This concept was further confirmed by Powell and Slater (1958) when they 
introduced dichloroisoproterenol (DCI), the first series of drugs 
capable of blocking p-adrenergic receptors response. The structural 
analogs of isoproterenol were then synthesised and made available by 
Biel and Lum (1966) and Moran (1967). It was thus possible to 
distinguish a ~  and p -  adrenoceptors not only on the relative potency 
of agonists, but also on the types of antagonists which could prevent 
the response in question.
Phentolamine, phenoxybenzamine and dibenamine blocked the 
a-receptors response; while p-adrenoceptors blocking agents include 
DCI, propanolol, practolol and alprenolol(Bradford, 1986).
Depending on the pharmacological properties of drugs in various 
tissue systems, a-adrenoceptors are further sub-classified into 
(X^-postsynaptic and a^-presynaptic adrenoceptors (Langer, 1974;
Doxy, 1977; Bethelsen and Pettinger, 1977). a^-adrenoceptor 
response are blocked by its selective antagonist, prazosin (Cambridge 
et al., 1977), and Ot^-adrenoceptors are preferentially blocked by 
yohimbine (Starke et al., 1975). The hypothesis of separate (X^- 
and a^-adrenoceptors are further supported by ligand binding studies
- 10 -
with labelled catecholamine antagonists (Miach et al., 1980? U ’Prichard
et al., 1979; Wood et al., 1979). Recently, based on radioligand
binding studies Kawahara and Bylund (1985) and Boyajian et al. (1987;
1988) proposed that a receptors may be divided into a and a
2 2A 2B
subtypes. The occurence of a and a adrenergic receptor
2A 2B
subtypes has been confirmed by Kobilka (1987). In addition an a
2C
subtype has been identified (Kobilka, 1987). Similarly,
(X ^-adrenoceptors can be subdivided into OC^ and OC ^  (Bylund,
1988). Based on the functional effects of {3-adrenoceptors, Land
et al., (1967) subdivided {3-adrenoceptors into and
Examples of {3^  selective antagonists are practolol, atenolol,
metoprolol and p-oxprenolol; and {^-selective agonists are zinteral
(NJ 1999), terbutalin and salbutamol (Minneman et al., 1980; Synder
et al., 1980). It is possible to measure {3-adrenoceptors directly by
3
specific binding of high-affinity antagonists [ H] dihydroalprenolol
125 3
and [ I] iodohydroxy-benzylpindolol and the agonist [ H]
hydroxybenzyl- isoproterenol (William et al., 1978). Some drugs used
in the study of adrenoceptors are as shown in Table 1.
_ Guanine nucleotide-binding regulatory (G) proteins couple
hormone and neurotransmitters receptors to second messenger systems.
The present classification of adrenoceptors suggests that each of the
four major subtype's is coupled to a different class of G-protein.
Both {3^  and {3^  are coupled to the stimulation of adenylate
cyclase of Gs, whereas a , a and a are coupled to the
2A 2B 2C
inhibition of adenylate cyclase of Gi (Bylund, 1988). Recently it is 
proposed that a^-adrenoceptors are coupled to an unknown G protein 
(Gx) leading to the breakdown of phosphotidyl-inositol breakdown 
(Litosch and Fain, 1986). Thus, the four major adrenoceptor subtypes 
are coupled to a different G protein and is illustrated as in Figure 5.
- 11 -
Table 1 Some drugs interacting with noradrenergic receptors
a  f p - agonist 
CC-agonist 
OC 2- agonist 
OC2-agonist
CC-antagonists
Ctj-antagonists
(X2-antagonists 
{3-antagonist 
^-antagonist 
P-agonist 
P 2-agonists
$l-agonist
^-antagonists
Noradrenaline
Adrenaline
phenylephrine
clonidine, UK 14304-18, 
oxymetazoline BHT-920, BHT-933, 
xylazine, 1-NA tramazoline
phentolamine, phenoxybenzamine, 
dibenanime
prazosin, indoramine, WB-4101, 
labetolol, UK 33274
yohimbine, piperoxan, rauwolscine
1-propranolol
butoxamine, ICI 118 551
isoprenaline
zinterol (MJ 1999), terbutalin, 
sabultamol
tazolol
antenolol, metonolol, practolol, 
p-oxprenolol
- 12 -
Adrenoceptors
^  ' I  |
p^-adrenoceptor p2-adrenoceptor ot2"a<^ renocePtor oc^-adrenoceptor
Coupled to Gj Coupled to Gx
Coupled to Gs
a2A a2B a2C a lA  a lB
Figure 5 Classification of adrenoceptors
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1.2.4 Storage of catecholaminergic neurotransmitter
Most catecholaminergic neurotransmitters are stored in the
granular or dense core vesicles found at the nerve terminals. During
biosynthesis, dopamine is actively transported into the granular or
2+
synaptic vesicles via an ATP+Mg -dependent carrier (Bianchi et al., 
1984). Noradrenergic vesicles can be identified by the presence of the 
enzyme dopamine- ^ -hydroxylase (DBH) in its membrane. This enzyme 
catalyses the conversion of dopamine to noradrenaline in the granular 
vesicles. Agents that deplete the neurotransmitter store, e.g. 
reserpine, also remove the dense core (Van Orden et al., 1967). The 
vesicular uptake process has a broad substrate., specificity for other 
phenylethylamines, including tryptamine, tyramine and amphetamine; 
these amines act as indirect sympatomimetic agents and compete with the 
endogenous catecholamines for the vesicular storage capacity. These 
phenylethylamines can thus stimulate the release of NA by displacing 
from its vesicles (Nieoullon et al., 1977; De .BefSeroche et al., 1976; 
Arnold et al., 1977).
There is evidence that DA is not retained as well as NA by large 
dense core vesicles prepared from bovine splenic nerve (Klein, 1982).
From the study using the crude vesicle associated fractions, it is found
3 3
that [ H ]NA retained more stable than [ H]DA because a more stable
interaction of the former with ATP was promoted by its {3-hydroxy group
3
(Weiner, and Jardetsky, 1964), also [ H]NA was found to be more 
resistant to the catecholamine depleting effect of reserpine and its 
analogs (Bianchi et al., 1984).
- 14 -
1.2.5. Release of catecholaminergic neurotransmitters
1.2.5.1 Evidence for the release of noradrenaline via exocytosis
In exocytosis, the expulsion of vesicular contents into the 
extracellular fluids is achieved by the fusion of the vesicular membrane 
with that of nerve terminal (Fig. 6) (Bowman and Rand, 1980). Evidence 
for exocytosis is largely based on chemical analysis and freeze-fracture 
study using electron microscope. A good example is the proportional 
release of NA and dopamine-[3-hydroxylase (DDH) from sympathetic nerves 
(Weinshilboum et al., 1971).
The soluble vesicular content of noradrenergic neurons are 
noradrenaline, ATP, enzyme DBH and large granule chromogranin A. The
demonstration that DBH, an enzyme of 300,000 Mr, is released 
concurrently and proportionately with NA established that the release of 
NA occurs via exocytotic process (Weinshilboum et al., 1971).
2+
1.2.5.2 Stimulus evoked Ca -dependent release of catecholaminergic 
neurotransmitter
Electrophysiological studies using squid axons, (Kat,2 and
Miledi, 1969) have shown that release of neurotransmitter is not only
dependent on nerve impulses. Depolarizing agents that affect the
ionic-channel permeability may also influence the neurotransmitter
2+
release, which has been shown to be Ca -dependent (Baker et al.,
1973; Kalz and Miledi, 1967; Nachshen, and Blaustein, 1980 and 1982;
Leslie et al., 1985 and Daniell and Leslie, 1986). Thus Taube (1977)
+ 3
showed that K -evoked or electrical stimulation of [ H]NA was
2+
abolished when Ca was omitted in the buffer medium. In contrast, 
the spontaneous non depolarization-evoked efflux of neurotransmitter is 
not calcium dependent.
Figure 6
- 15 -
Vesicles
Presynaptic neuron
«
Postsynaptic neuron
Exocytosis of a vesicle's content at the nerve terminal 
(From Bowman and Rand, 1980 textbook of pharmacology, 
2nd edition, Blackwell Scientific publication, pp 5.23)
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2+
Llinas et al. (1972; 1975) studied the influence of Ca on
synaptic transmission by first injecting aequorin into the pre- and
post-synaptic terminals of the squid giant synapse through micropipette.
2+
Aequorin is a bioluminiscent protein which reacts with Ca to produce
light (see Blinks et al., 1976 for review). The pre- and post-synaptic
terminals loaded with aequorin were activated by means of external
electrodes, and membrane depolarization which was capable of triggering
the release of synaptic transmitters also led to a substantial increase
in light emission. Thus, their results give direct evidence of the 
2+
influence of Ca in synaptic transmission.
1.3 Regulation of NA release by presynapitc (X^-adrenoceptors
NA released from both the peripheral (Langer, 1974; 1981) as
well as central nervous system (see Chesselet, 2984 for review) is able
to modulate the stimulated release of NA by either activating the
adrenoceptors situated on the presynaptic or postsynaptic membrane,
thereby leading to the changes in the physiological response via a
negative feedback mechanism. In brain, most studies on presynaptic
regulation of the release of NA are performed in vitro using
radiolabelled NA with either brain slices or synaptosomes (Middlemiss,
+
1988). Electrical stimulation or K depolarization evoked release of
radiolabelled NA from the peripheral and central nervous system (CNS)
can be inhibited by selective a^-adrenergic agonists, such as
clonidine (Starke et al., 1974; Medgett et al., 1978; Schoffelmeer et
al., 1986) and BHT-920 (Van Meel et al., 1981; Leus and Schmann, 1984;
Cichini and Singer, 1987). In addition, a more potent (X^-adrenergic
3
agonist such as UK 14304-18 on the regulation of [ H]NA release from 
the peripheral nervous system has also been pharmacologically
- 17 -
characterized (Cambridge and Davey, 1980; Cambridge, 1981; Van Meel
et al., 1981). While selective (X^-adrenergic antagonist such as.
yohimbine enhances the release of NA from both the peripheral (Langer,
1981) and central nervous system (Starke et al., 1975; Taube et al.,
1977). This is because OC^-adrenergic antagonists block the
inhibitory effect of NA, acting at presynaptic O^-adrenoceptors, on
its own release. The OC^-adrenergic agonist, phenylephrine and
(X^-antagonist, prazosin, did not have any effect on the release of NA
from the peripheral as well as central nervous system (Cambridge, et
al., 1977; Reichenbacher et al., 1982). In the CNS the {3-adrenergic
agonist, isoprenaline, does not affect the depolarization evoked release
3
of NA (Taube et al., 1977). Thus release of [ H]NA from the central 
nervous system is not mediated by |3-adrenoceptor. In support of this
the j3-adrenergic antagonist, propanolol, does not antagonise the
3
inhibitory effect of NA on the stimulated release of [ H]NA from the
-6
central nervous system (CNS) (up to 10 M) (Taube et al., 1977). In
contrast, isoprenaline enhances and propranolol is found to antagonise
3
the isoprenaline enhancement of [ H]NA release from the peripheral 
nervous system (Adler-Graschinisky and Langer, 1975; Celuch et al.,
1978; Dahlof et al., 1978). Furthermore at higher concentrations 
-5
(above 10 M), propranolol enhanced the inhibitory action of NA on
release. A possible explanation for this observation is that by
preventing NA from binding to (3-adrenoceptors its effective
concentration is increased, thus leading to greater inhibition of NA
release.(see Langer, 1981 for review).
In conclusion, activation of presynaptic a^-adrenoceptor
3
leads to the inhibition of stimulated release of [ H]NA from both the 
peripheral and the central nervous system. However, based on radio
- 18 -
ligand binding studies, it is found that OC^-adrenoceptors found in
the CNS are also present at the post-synaptic sites, since the same 
3
number of [ H] clonidine is found to bind to the rat cerebral cortex 
membranes after the pretreatment of the membrane fractions with 
6-hydroxydopamine, which function was to destroy presynaptic 
noradrenoceptors (U'Prichard and Snyder, 1979).
2+
1.3.1 Influence of CX ^ -adrenoceptors on voltage-sensitive Ca and 
+
K. channels
It has been suggested that (X^-adrenergic agonist inhibit the 
3
release of [ H ]NA from the peripheral as well as the central
2+
noradrenergic neurons by acting on voltage-sensitive Ca channels.
Thus (x2-adrenergic agonists inhibit depolarization-evoked 
2+
Ca -dependent release whereas the spontaneous efflux is not affected
(Gothert et al., 1979; Alberts et al., 1981; Schoffelmeer and Mulder,
1983, 1983b). Further support for this suggestions is provided by
electrophysiological studies which demonstrate that CC^-adrenergic
2+
agonists, NA and clonidine inhibit the voltage-sensitive Ca current
in embryonic chick dorsal root ganglion neurons (Dunlap and Fishbach,
1981) and in post-ganglionic neurons of the rat superior cervical
ganglion (Hons and Mcaffee, 1980) respectively, thereby reducing the 
2+
Ca inward current.
Electrophysiological studies show that a^-adrenoceptors 
situated on the cell bodies of noradrenergic neurons in the locus 
coeruleus (LC) are the same as the (X^-adrenoceptors found on nerve 
terminals in the peripheral as well as the central neurons system. For
example action potentials of neurons in the LC are inhibited by 
OC ^ -adrenergic agonists including adrenaline, noradrenaline (Svensson
- 19 -
et al., 1975; Cedarbaum and Aghajanian, 1976) and clonidine (Cedarbaum
and Aghajanian, 1976; Aghajanian and Van der Maalen, 1982) and the
inhibitory effect produced by these agonists can be blocked by the
a 2_adrenergic antagonist piperoxane but not the ^-adrenergic antagonist
satolol (Cedarbaum and Aghajanian, 1976). Activation of
a ^-adrenoceptors situated on the cell bodies of noradrenergic neurons
+
in the LC by clonidine is found to increase the K conductance leading 
to hyperpolarization of noradrenergic neurons in the CNS (Aghajanina and 
Van der Maalen, 1982).
Zimanyi et al. (1988) show that in the presence of selective
+
K channel blockers such as 4-aminopyridine (4-AP) and quinine, the 
inhibitory effect of CC ^ -adrenergic agonists including 1-NA and
xylazine are reduced, while the enhancing effect of OC^-adrenergic
3
antagonist yohimbine on electrically stimulated release of [ HjNA from
the peripheral noradrenergic nerve terminals are completely abolished.
+
The effect of 4-AP is to selectively block the voltage-dependent K
permeability (Meves and Pichon, 1977), and that of quinine is to block
2+ + 
the Ca -activated K conductance (Cherubini et al., 1984;
Bartschat and Blaustein, 1985). Thus, OC^-adrenergic agonists
inhibit the release of NA from the peripheral noradrenergic neurons
+
primarily through hyperpolarization resulting from increased K 
permeability.
Schoffelmeer and Mulder (1984) suggest that Ot^-adrenoceptors 
located on noradrenergic axonal varicosities, unlike those located on 
the cell bodies and the peripheral nerve terminal, do not primarily
mediate hyperpolarization of the neuronal membrane. Thus NA and
+ 3
clonidine inhibit 13mM K -stimulated release of [ HJNA in the
2+ + 
presence of 1.2mM Ca to the same extent as 56mM K -stimulated
- 20 -
release of [ H]NA in the presence of O.lmM Ca . According to
them, the diminished inhibitory effect of both NA and clonidine on 56mM
+ 3 2+
K -stimulated released of [ H]NA in the presence of 1.2mM Ca may
2+
be due to the effect of high Ca influx during depolarization leading 
to the oversaturation of release mechanism. Thus, their data strongly
argue against the general view that OC^-adrenergic agonists inhibit the
+ 3
K -stimulated release of [ H]NA via hyperpolarization of
noradrenergic nerve terminals during depolarization in the CNS.
1.3.2 Possible role of cAMP in the regulation of NA release
Depolarization leads to the increase in intracellular cAMP 
levels in brain slices (Shimizu et al., 1970; Shimizu and Daly, 1972? 
Zanella and Rail, 1973; Ferrendelli et al., 1976) as well as in 
synaptosomes (Daly et al., 1980). Indirect evidence for a role of cAMP 
in synaptic transmission can be studied by using non-hydrolysable 
membrane penetrating cAMP analogue including db-cAMP and 8-Br-cAMP, and 
the adenylate cyclase activators, NaF and forskolin (Wermer et al.,
N
1982; Schoffelmeer et al., 1983). Db-cAMP has been reported to
enhance the electrical stimulated release of acetylcholine (Goldberg and
Singer, 1969) and NA (Wooten et al., 1972) from the peripheral nervous
system (PNS). In the CNS, db-cAMP, 8-Br-cAMP, and forskolin enhanced
the electrical (Markstein et al., 1984; Schoffelmeer et al., 1985,
+
1986) K (Wermer et al., 1982) and veratrine (Schoffelmeer et al.,
3
1983) induced release of [ H]NA from rat brain slices (Wermer et al.,
1982? Markstein et al., 1984; Schoffelmeer et al., 1982, 1986) and
synaptosomes (Schoffelmeer et al., 1985), without affecting the
3
spontaneous efflux of [ H]NA (Schoffelmeer et al., 1983, 1985).
However, Rabe et al. (1982) demonstrated that the forskolin
- 21 -
enhancement of K -stimulated release of [ H]NA from rat PC 12
pheochromocytoma cell line is biphasic with facilitation by O.T-lOuM
forskolin but inhibition at lOOuM. They thus conclude that elevation
of intracellular cAMP cannot initiate release, but can enhance
depolarization dependent release of NA.
Electrophysiological studies in neurons from suboesophageal
ganglia of Helix aspersa demonstrate that intracellular perfusion with
cAMP or intracellular application of ATP, at nanomolar concentration
2+
cause a slight increase in Ca current (ICa) (Yatani et al., 1982).
In addition, intracellular injection of cAMP or application of serotonin
to the cell body of Aplysia californica caused a prolonged and complete
+
closure of individual K channels (Klein and Kandel, 1978; Siegelbaum
et al., 1982) leading to a longer action potential and hence a
2+ 2+ 
prolongation of Ca influx into the cell. Since Ca influx is
associated with the release of neurotransmitter, it is then suggested 
2+
that cAMP and Ca may act closely as interrelated second messengers 
involved in the stimulus-secretion coupling process.
PDE inhibitors, that prevent the breakdown of cAMP^including
3
IBMX and ZK 62771^increase the electrically evoked release of [ H]NA
from rat brain slices (Markstein et al., 1984; Schoffelmeer et al.,
1985, 1986) and synaptosomes (Schoffelmeer et al., 1985). In contrast,
PDE-inhibitors including RO 20-1724, IBMX, 7-benzyl-IBMX and ZK 62771
+
inhibited the 13mM K (Werner et al., 1982) and veratrine (Schoffelmeer
3
et al., 1983) induced release of [ H]NA from rat neocortical brain
slices. However, ZK 62771 is able to enhance the K+-stimulated
3 + channel
release of [ H]NA in the presence of Na ^blocker, TTX. This
indirectly suggests that PDE inhibitors may also possibly act as a Na channel 
blocker. Till a more selective PDE inhibitor is available, it is
- 22 -
difficult to interpret the cAMP effect with the existing PDE
inhibitor. For example, IBMX which is a PDE inhibitor has also been
reported to be a potent adenosine receptor antagonist (Stiles, 1986).
a 2~Adrenergic agonists have been reported to inhibit cAMP
formation in a number of tissues, including cultures of astrocytes
derived from mouse (Van Calker et al., 1978) and rat brain (McCarthy
et al., 1979), mouse neuroblastoma X glioma cells, NG 108-15 cells
(Sabol and Nirenberg, 1979; Griffi et al., 1985) human (Burns et al.,
1982) and hamster adipocytes (Fain and Garcia-Sainz, 1980; Garcia-Sainz
et al., 1980). In addition, activation of a^-adrenoceptors has been
shown to mediate inhibition of adenylate cyclase activity stimulated by
forskolin in rat cerebral cortical membrane (Kitamura et al., 1985).
In contrast, in intact brain slices and synaptosomes, there is no direct
evidence to show that Ot^-adrenergic agonist inhibits the stimulated 
3
release of [ H]NA by decreasing the intracellular cAMP levels.
However, inhibitory effect of a^-adrenergic agonists, including
clonidine (Schoffelmeer et al., 1983, 1986), oxymetazolin (Werner
et al., 1982) and the enhancement effect of (X -adrenergic antagonist
+
phentolamine on electrical (Schoffelmeer et al., 1986), K (Werner
et al., 1982) and veratine (Schoffelmeer et al., 1983) induced release 
3
of [ H]NA are strongly reduced in the presence of 8-Br-cAMP and 
db-cAMP. Furthermore, the inhibitory effect of oxymetazoline and the 
enhancement effect of phentolamine are also reduced in the presence of 
NaF, a potent activator of adenylate cyclase (Werner et al., 1982).
Thus, the findings indirectly support the role of cAMP in presynaptic 
regulation of NA release.
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Unlike many peripheral tissue, mammalian brain contains adenylate
2+
cyclase (EC 4.6.1.1) activity that is stimulated by Ca via the 
2+
endogenous Ca binding protein, calmodulin (CaM) (Brostrom et al.,
1977; Cheung, 1980). In turn, cAMP may lead to the phosphorylation of
2+  2+
Ca channels, thereby enhancing their Ca conductance (Reuter,
2+
1983), thus increasing the availability of Ca for secretory
2+
processes. However, phosphorylation by Ca and calmodulin may act
in parallel or synergistically with phosphorylation of intracellular
cAMP dependent proteins, some of which are located in synaptic vesicles,
thereby indirectly leading to the exocytotic process (Nestler and
Greengard, 1983). Moreover, in synaptic vesicles and nerve terminal
2+
membrane, cAMP and Ca have been shown to regulate phospholipase A2 
activity, which may play an essential role in the exocytotic process
(Moskowitz et al., 1983, 1984). Thus, it would be interesting to know
3
whether (X^-adrenergic inhibition of stimulated release of [ H]NA is
2+
directly affected by the Ca influx or by the regulation of
intracellular cAMP levels.
2+
Ca ionophore, which helps to transport the extracellular
2+  _ "2 1*
Ca into the nerve terminals by artif iciall-y ■ open up the Ca-
3
-eh-afmcl, induced release of [ H]NA from rat brain slices. Clonidine
and phentolamine do not have any effect on, while forskolin and
2+ 3
8-Br-cAMP enhanced the Ca ionophore induced release of [ H]NA
(Schoffelmeer, 1986). This suggests that forskolin and 8-Br-cAMP can
3
enhance the stimulated release of [ H]NA without effecting voltage 
2+
sensitive Ca channels. Clonidine inhibits and phentolamine further
2+
enhanced the forskolin enhancement effect of Ca ionophore induced 
3
release of [ H]NA, while they remain without any effect on 8-Br-cAMP 
enhancement effect (Schoffelmeer, 1986). Thus, it is suggested that
- 24 -
forskolin and 8-Br-cAMP operate via separate mechanisms, and that
3
clonidine may inhibit the release of [HJNA by inhibiting the
adenylate cyclase activity stimulated by forskolin, thus decreasing
intracellular cAMP formation. Until more direct evidence is obtained,
the hypothesis that ^-adrenergic agonist inhibits the stimulated 
3
release of [ HJNA by decreasing cAMP levels in the CNS is inconclusive 
and remains a speculation.
1.3.3 Possible relationship between adenosine and CC^-adrenoceptors 
on the regulation of NA release
It is well established that ATP is released together with 
catecholamines from the adrenergic nerve terminals (Burnstock, 1981).
The levels of extracellular adenosine concentrations in the brain tissue 
were found to be in a low micromolar range (Dunwiddie et al., 1981; 
Zetterstrom et al., 1982). In electrophysiological experiments, both 
spontaneous and evoked synaptic transmission were depressed by adenosine 
(Krentzberg et al., 1983), the effects of which are antagonised by 
adenosine receptor antagonists, such as the methylxanthines (Jackisch 
et al., 1985).
In the CNS, the depolarization-evoked release of several
neurotransmitters including noradrenaline (Harms et al., 1978; Jonzon
and Fredholm, 1984; Jackish et al., 1985; Allagier, 1987), dopamine
(Harms et al., 1979; Jarvis and Williams, 1987), acetycholine (Pedata
et al., 1983b; Corradetti et al., 1984; Jackisch et al., 1984),
serotonin (5-HT) (Harms et al., 1979), glutamate (Dolphin and Archer,
1983) and GABA (Hollins and Stone, 1980) is inhibited by adenosine.
45 2+
Adenosine decreases Ca uptake into synpatosomes during
depolarization (Wu et al., 1982; Silinsky, 1986), which suggests that
24-
adenosine inhibits neurotransmitter release by reducing Ca influx.
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In addition, the adenosine depression: of synaptic transmission is
+ + 
blocked by K -channel blockers suggesting that adenosine enhances K
conductance in nerve terminals (Perkins and Stone, 1980; Scholfield,
1986).
When rat brain slices were treated either with N-ethylmaleimide
many proteins including
(NEM) which inactivates^the guanine nucleotide-binding protein
(G-protein) (Allagier, 1987), and pertussis toxin (IAP) which
ADP-ribosylate the inhibitory G-proteins (Fredholm and Lindgren, 1987),
the inhibitory effects of adenosine on the stimulated release of
noradrenergic neurotransmitters from the rabbit hippocampal brain slices
was reduced. These findings suggest that the depolarization-evoked
release of NA is modulated by adenosine receptors linked to a G-protein.
Radioligand binding studies show that adenosine interacts with
specific adenosine receptors in the CNS (Williams and Risley, 1980; Wu
et al., 1980; Patel et al., 1982). These receptors are subclassified
into A or (Ri) and A (or Ra) receptors. The A or (Ri)
1 2 1
receptors have a high (nanomolar) affinity for adenosine while A^ or 
(Ra) have a lower (micromolar) affinity for adenosine which either 
inhibit or activate adenylate activity (Van Calker et al., 1979; Londos 
et al., 1980) respectively. The 'R' nomenclature was initially 
suggested since the ribose portion of the adenosine molecule had to be 
intact for adenylate cyclase activity (Londos and Wolff, 1977).
Adenosine A^ and A^ receptors can now be distinguished by
various synthetic and enzyme stable adenosine analogues. For example,
6 6 
N -substituted derivatives of adenosine including N -cyclohexyl
6
adenosine (CHA) and N -phenylisopropryl adenosine (R-PIA) are more 
potent at activating A^ receptors, which are often linked to a 
decrease in the formation of cAMP. In contrast, 5'-N-ethylcarboxamido
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adenosine (NECA) is more potent than CHA or R-PIA at activating A^
receptors, leading to increase in intracellular cAMP formation in the
cell or tissue studied (Fredholm and Dunwiddie, 1988). In addition
adenosine 'P' sites have also been described (Stiles, 1986). The 'P'
stie is a putative site on the catalytic unit through which ribose
modified adenosine analogs directly inhibit adenylate cyclase activity
(Stiles, 1986). However, adenosine 'P' sites are sometimes designated
when the purine portion of the adenosine molecule is required for the
inhibition of adenylate cyclase activity (Londos and Wolff, 1977, 1980).
Stiles (1986) suggests that in brain slices, activation of
A^-receptor leads to the inhibition of neurotransmitter release,
whereas, activation of A^-receptor leads to the increase of
neurotransmitter release. In rabbit hippocampal brain slices, the
3 3
electrically stimulated release of [ H]NA and [ H]-ACh . are
inhibited by various adenosine agonists with the following order of
potency: CHA> [(-)PIA] >  NECA >  2-chloro-adenosine >  adenosine >  ATP,
effects which are reversed by adenosine receptor antagonists, the
methylzanthines including theophylline, 8-theophylline and IBMX (Jackish
et al., 1984, 1985). It is concluded that adenosine inhibit the
3
electrically-stimulated release of [ H ]NA from rabbit hippocampal
brain slices via adenosine A^-receptors. Since NA also inhibits the
3
electrically-stimulated release of [ H]NA via OC^-adrenoceptors, 
question then arises as to the contributory effect of adenosine on
noradrenergic neurotransmitters release. Inhibitory effect of
3
adenosine on electrically-stimulated release ( H]NA from rat brain 
slices is not antagonised by the a^-adrenoceptor antagonist, 
yohimbine (Reichenbacher et al., 1982), and the results suggest that 
adenosine does not act at a CC^-adrenoceptor. In contrast, Allgaier
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et al. (1987) found that the inhibitory effect of the adenosine
A^-receptor agonist, (-)PIA on electrically-stimulated release of 
3
[ H]NA from rabbit hippocampal brain slices is further enhanced by
yohimbine. The results suggest that adenosine A^-receptor acts
synergistically with a^-adrenoceptor in the regulation of NA release
from rabbit hippocampal brain slices. This controversy may actually be
between
due to the differences^- animal species.
1.4 Cyclic AMP in various rat brain regions
Brain was shown to contain a higher level of adenylate cyclase 
and PDE acitivites than in other tissue systems (Sutherland, et al., 
1962). Adenylate cyclase is a membrane bound enzyme which is 
responsible for the conversion of ATP to cAMP and PDE catalyses the 
conversion of cAMP to 5 'AMP. The concentrations of cAMP in various rat 
brain regions was then studied by Schmidt, et al. (1971) using microwave 
irradiation technique, since cAMP was shown to be stable to heat 
(Sutherland, et al., 1958). Concentrations of cAMP found was: 
cerebellum = brain stem> hypothalamus mid-brain >  hippocampus = 
cortex. On the contrary, Weiss and Costa (1968) showed that the 
PDE-activities in the brain were: cortex-hippocampus >  hypothalamus>-
medulla-pons> cerebellum. This suggests that those parts of the brain 
which contains higher adenylate cyclase acitivites has lower PDE 
activities and vice versa.
1.5 Regulation of cAMP levels in intact brain slices 
Adenylate cyclase activity in the brain may be activated by
hormones and neurotransmitters, which catalyses the conversion of ATP to 
cAMP and pyrophosphate (PP).
- 28 -
ATP Adenylate cyclase cAMP + PP 
GTP, Mg2+
Krishna et al. (1968) described a simple method for the assay of
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adenylate cyclase in tissue homogenates by using either [a- , P]-,
14 3
[ C]- and [ H ]-ATP as substrates, but this is not possible with
slices of brain because ATP does not easily penetrate unbroken cells.
14
However, Santos et al. (1968) found that [8- C] adenine, which is 
actively transported into slices of brain, is converted to ATP, which in
is
turny^converted to cAMP. Shimizu et al. (1969) found that the technique
developed by Santos et al. (1968) is excellent for measuring the
neurotransmitter mediated changes in intracellular cAMP content in brain
slices. Schmidt et al. (1971, 1972) found that immediately following
decapitation there is a rapid and substantial increase in cAMP levels in
the brain. In order to obtain a stable and relatively low basal value
of cAMP in the brain slices, it is necessary to preincubate the brain
slices in the normal buffer medium for about 15 minutes before
14
incubating it with [ C] adenine following by 10 minutes post­
incubation period (Schultz and Daly, 1973a). Earlier studies using 
radiolabelling techniques demonstrate that neurotransmitters such as NA, 
serotonin and histamine elicited cAMP accumulation in brain slices 
(Kakiuchi et al., 1968a, 1968b; Shimizu et al., 1970; Rail and Sattin, 
1970; Schultz and Daly, 1973a). However, the effects of NA, serotonin 
and histamine are greatly reduced or absent when tested in incubated 
homogenates of brain (Klainer et al., 1962; Voigt and Krishna, 1967). 
The magnitude of biogenic amines response varies between different 
animal species and the region of the brain from which slices are 
prepared. For example, NA which elicits marked accumulation of cAMP in 
cerebral cortical slices from rat (Rail and Sattin, 1970; Shimizu
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et al., 1970; Forn and Krishna, 1971) has either no effect or a minimal 
effect in cortical slices from guinea pig (Kakiuchi et al., 1969;
Schultz and Daly, 1973a) and rabbit (Kakiuchi and Hall, 1968b). In 
addition, NA is more active than histamine in rabbit cerebellum 
(Kakiuchi and Rail, 1968a) but less active in cerebral cortex (Kakiuchi 
and Rail, 1968b).
1*5.1 Adenylate cyclase
It is now established that hormone-sensitive adenylate cyclase
is regulated by stimulatory receptors (Rs) and inhibitory receptors (Ri)
which activate the catalyst adenylate cyclase (C) through the
heterotrimeric regulatory GTP binding proteins, Gs ( a sr p and y  ) an<^  Gi 
oc
( i, (5 and y  ) (Gilman, 1984; Schramm and Selinger, 1984; Taylor and 
Merritt, 1986; Thomas and Hoffman, 1987). The hydrophilic a-subunits
are associated with the two hydrophobic subunits, p and y . The 
actions of Gs and Gi are not symmetric since Gs associates tightly with 
C, whereas Gi does not (Levitzki, 1987). The structure of hormone- 
sensitive adenylate cyclase is as illustrated in Figure 7. The 
regulatory proteins (Gs and Gi), in addition to binding GTP, appear to 
be associated with GTPase activity which terminate the activation of the 
G-proteins. G-proteins play a key role in coupling process by which 
the hormone-bound receptor conveys activation upon the catayltic unit, 
which in turn catalyses the conversion of ATP to cAMP.
The receptors (Rs and Ri) are hydrophobic with seven 
membrane-spanning domains (Levitzki, 1987). Activation of Rs by 
stimulatory hormones (Hs) leads to the dissociation of subunits of Gs,
fy j I
s and p y  . The (X -subunit activates C, resulting in the
3
accumulation of cAMP within the cell (Thomas and Hoffman, 1987).
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Figure 7 The structure of hormone-sensitive adenylate cyclase
The receptors are highly hydrophobic with seven 
membrane-spanning domains. The p-subunits of Gg and G. are 
embedded in the membrane bilayer. The 0C-subunits are bound to 
the -subunits but are themselves hydrophobic. The
(X-subunit interacts with Rg and the catalyst C, probably through 
unique sequences in the cytoplasmic domains.
(From Levitzki, A., Trends in Pharmacological Sciences 8,, 299-303 
(1987)).
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cAMP may then activate cAMP-dependent protein kinase, resulting in the 
phosphorylation of specific protein substrates (Nestler and Greengard,
1983). However, activation of inhibitory receptors (Ri) by inhibitory 
hormones (Hi) leads to the dissociation of subunits of Gi, a i and P Y  • 
Inhibition of adenylate cyclase probably occurs directly via
ff
i inhibition of C or indirectly by inactivation of C (Thomas and 
Hoffmann, 1987). This leads to the fall in intracellular cAMP levels, 
and decreases in the protein kinase activity. Some examples of 
stimulatory and inhibitory hormones receptors that coupled to the 
adenylate 'cyclase are as depicted in Table 2.
1.5.2 Receptor^-mediated cAMP formation
1.5.2.1 (X - and ^ -Adrenergic agents (Noradrenaline)
Stimulation of the locus coeruleus has been shown to increase 
cAMP levels in the cortex, hippocampus, striatum and hypothalamus 
leading to the release of NA (Bloom, 1975; Korf and Sebens, 1979). 
Considerable evidence exists that NA stimulates cAMP formation in many 
brain regions by activating a- and -adrenergic receptors, since the 
NA response on cAMP formation is more potently blocked by 
Ot^-adrenergic antagonist, prazosine and |3-adrenergic antagonist, 
propranolol than by CC^-adrenergic antagonist, yohimbine (Perkin and 
Moore, 1973; Davis et al., 1978; Daly et al., 1980; Johnson and 
Minneman, 1986). This is further supported by the findings of Etgen 
et al. (1987), who demonstrate that p-adrenergic agonist stimulation of 
cAMP formations in rat hypothalamus brain slices is potentiated by 
(X ^ -adrenergic agonist, phenylephrine but not (X^-adrenergic 
agonist, clonidine. In contrast, Pile and Enna (1986) found that 
isoprenaline stimulation of cAMP formation in rat neocortical brain
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Table 2 Examples of stimulatory and inhibitory hormone receptors that
couple to the adenylate cyclase
Stimulatory receptors Inhibitory receptors
(Ra) (Ri)
J3 -Adrenergic Cc ^ “Adrenergic
Adenosine (A ) Adenosine (A )
2 1
Dopamine (D^) Dopamine (D^)
ACTH Muscarinic
Glucagon Opiates (Enkephalin/morphine (p)
Prostaglandin (E^) Somatostatin
Vasointestinal peptide (VIP) 
Vasopressin (v ^^
Angiotensin (II)
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slices is potentiated by clonidine but not phenylephrine. Furthermore, 
they reported that isoprenaline and a-adrenergic agonist,
6-fluoronorepinephrine stimulation of cAMP formation is more potently 
blocked by yohimbine than by prazosin They thus suggest that NA 
stimulation of cAMP formation via the synergistic effect of an^
P-adrenoceptors.
Destruction of presynaptic noradrenergic nerve terminals with 
6-hydroxydopamine results in enhanced responsiveness of cAMP-generating 
systems by both a- and p-adrenoceptors (Huang et al., 1973; Kalisker 
et al-., 1973). The findings suggest that these receptors may also be 
located post-synaptically.
Activation of CC^-adrenoceptors have been shown to inhibit 
cAMP formation in a number of tissues, including human (Burns et al.,
1982) and hamster adipocytes (Garcia-Sainz et al., 1980), mouse 
Neuroblastoma X glioma cells, NG 108-15 cells (Sabol and Nirenberg,
1979) and cultures of astrocytes derived from mouse (Van Calker et al.,
1978) and rat brain (McCarthy et al., 1979). So far, there is no 
direct evidence which shows that activation of oc^-adrenoceptors 
linked to the inhibition of cAMP formation in brain slices since the 
CX^-adrenergic agonist, clonidine inhibition of NA stimulation of cAMP 
formation in rat neocortical brain slices is not reversed by 
CC^-adrenergic antagonist (Pile and Enna, 1986).
NA stimulation of cAMP formation in rat cerebral cortex and 
hypothalamus may involved PGE^ since the effect of NA is decreased by 
the protoglandin synthetase inhibitors indomethacin, aspirin and 
acetominophan and this could be reversed by PGE^ (Partington et al.,
1980).
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Daly et al. (1980) demonstrate that in slices of rat cerebral 
cortex, the a-adrenergic agonist, 6-fluoronorepinephrine and 
the [3-adrenergic agonist, 2-fluoronorepinephrine stimulation of cAMP 
formation can be blocked by 8-phenyl theophylline and propranolol, 
respectively. The finding suggests that OC-adrenergic response is 
dependent on adenosine. Furthermore, adenosine or histamine 
potentiated NA and 6-fluoronorepinephrine but not |3 -adrenergic agonist, 
2-fluoronorepinephrine stimulation of cAMP formation. The results show 
that (X-adrenoceptor acts as a receptor modulator leading to the 
potentiation of adenosine, histamine and p-adrenoceptors stimulation of 
cAMP formation. In contrast, a-adrenoceptor does not elicit any 
response in cerebellum (Daly et al., 1980).
NA at high concentrations may also activate dopamine-sensitive 
cyclases. This is the reason why NA is able to stimulate cAMP levels 
in slices of caudate nucleus (Forn et al., 1974).
1.5.2.2 Adenosine
Adenosine stimulates cAMP formation 20-30 fold in guinea pig 
cortex slices, and the effect can be blocked by methylxanthines 
including theophylline and caffeine (Satin and Rail, 1970). However, 
in guinea pig particulate preparation, adenosine is only able to 
stimulate cAMP formation 4 fold (Daly et al., 1980).
It was initially presumed that adenosine increased cAMP 
formation by increasing the availability of substrate ATP for enzymes 
adenylate cyclase. However, using deoxy ATP, which does not give rise 
to adenosine in the assay medium, Cooper et al. (1980) show that 
adenylate cyclase in rat cerebral cortex is inhibited by low 
concentration of adenosine. In addition, adenosine analogue such as
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phenylisopropyladenosine (PIA) and N -cyclohexyladenosine (CHA) are 
able to exert their effect on adenylate cyclase activity in a biphasic 
manner i.e. in the presence of GTP, low concentration lOnM of the 
analogue inhibits and high concentration above luM stimulates adenyl 
cyclase activity. The inhibitory effect of the adenosine analogue is 
antagonised by IBMX (Ki, 0.45uM). Van Calker et al. (1979) also 
demonstrate a high affinity inhibitory site (nanomolar) and a low 
affinity stimulatory site (micromolar) from the studies on adenosine 
stimulation of cAMP formation in glial cell cultures, which they termed 
A^ and A^ respectively. In rat brain slices, adenosine uptake 
inhibitors such as dipyridamole, hexobendine and
p-nitrophenylthioguanosine were found to significantly potentiate the 
response to low concentrations of adenosine stimulation of cAMP 
formation. The finding suggests that adenosine stimulates cAMP 
formation by activating the adenosine receptors located on the 
extracellular sites.
Adenosine have also been shown to potentiate biogenic amines
including NA, serotonin and histamine (Sattin and Rail, 1970; Schultz
and Daly, 1973; Daly et al., 1980; Daum et al., 1982), glutamate and
+
aspartate (Shimizu et al., 1974) and K (Huang et al., 1971) 
stimulation of cAMP formation in brain slices, and their effects can be 
blocked by adenosine antagonists, methylxanthines.
1.5.3 Forskolin stimulation of adenylate cyclase
The diterpene forskolin, isolated from the roots of the Indian 
medicinal plant Coleus forskohlii (Bhat et al., 1977) has been shown to 
directly stimulate the catalytic unit of the adenylate cyclase by 
passing the guanine nucleotide regulatory proteins, Gs and Gi (see Daly, 
1984 for review).
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Low concentrations of forskolin, which alone have no effect on 
adenylate cyclase activity, are able to potentiate agonist stimulations, 
thereby increasing the potency and/or efficacy of the agonists. This 
suggests that forskolin may interact synergistically with Gs (Daly 
et al., 1982; Seamon and Daly, 1983). A two-site model of forskolin 
action in C6-2B rat astrocytoma cells was proposed by Borovsky et al. 
(1984), who suggested that a low affinity site which mediates the direct 
action of forskolin to increase intracellular cAMP accumulation and a 
high-affinity site which mediates the potentiation of forskolin exist.
The actual mechanism(s) and site(s) of forskolin action are 
still unknown. It has been suggested that forskolin may stimulate 
adenylate cyclase activity via an unknown regulatory protein that is not 
linked to hormone receptors and Gs (Brooker et al., 1983).
1.5.4 Effect of depolarization on cAMP formation
Electrical stimulation (KaKiuchi et al., 1969; Zanella and
Rail, 1973) as well as membrane depolarization by various depolarizing
+
agents including high concentrations of K , batrochotoxin, veratrine, 
ouabain (Shimizu et al., 1970, 1973; Shimizu and Daly, 1972) cause an 
increase in intracellular cAMP formation in guinea pig cerebral cortex
slices. The effects of these depolarizing agents are found to be
2+ 2+ 
depended on Ca concentrations since the absence of Ca
concentrations inhibit depolarization induced cAMP formation. In
2+
addition,Schwabe et al. (1978) demonstrate that the addition of Ca 
chelator, EGTA to guinea pig cortical slices acutely reduce 
extracellular calcium increased basal levels of cAMP formation. 
Similarly, the addition of theophylline, an adenosine antagonist 
(Schwabe et al., 1978) has also been found to inhibit electrical
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(KaKiuchi et al., 1969) as well as ouabain, batrachotoxin, veratrine and
+
high concentrations of K (KaKiuchi et al., 1969; Shimizu et al.,
1970; Shimizu and Daly, 1972) stimulation of cAMP formation in guinea
pig cerebral cortex slices. The findings thus suggest that
2+
depolarization which increases Ca influx may lead to the release of 
endogenous adenosine which in turn stimulates cAMP formation via 
external adenosine receptors.
2+
1.5.5 Ca /Calmodulin regulation of neuronal cAMP levels
Neuronal cAMP levels have been shown to be regulated by 
2+
calmodulin (CaM), a Ca -binding protein since the latter is able to 
stimulate both adenylate cyclase (Brostrom et al., 1977; Wolff and 
Brostrom, 1979) and phosphodiesterase (Cox et al., 1981) activities.
Native calmodulin (CaM) is inactive and contains four high affinity
2+  ...   . _ —  —  —  —  —  - —  '
Ca -binding domains (Watterson et al., 1980) and six auxiliary
2 +
ion-binding sites (Cox, 1988). Divalent ion such as Mg can
modulate the affinity of CaM by occupying the auxiliary sites which are
2+ 2+ 
more specific for Mg , and less so for Ca (Cox, 1988).
2+
Brostrom et al. (1977) demonstrate that Ca exhibits a 
biphasic response on adenylate cyclase activities in rat cerebral
cortical membrane when CaM is present in the assay medium; that is, low
2+ 2+
Ca concentrations CT-O.lmM) activates and high Ca concentrations
(< 0.5mM) inhibit the activity. In addition, the inhibitory effect of 
2+
high Ca concentrations on the adenylate cyclase activity in the 
presence of CaM can be reversed by the addition of EGTA to the assay 
medium.
The exact mechanism(s) of CaM are still unknown since there are 
evidences which suggest that CaM may either stimulate cAMP formation by
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directly activating the catalytic subunit (C) independent of the 
GTP-binding protein (Seamon and Daly, 1982), or interacts with guanyl 
nucleotides in an additive (Seamon and Daly, 1982) or synerigstic 
(Heideman et al., 1982) manner.
1 .6 Modulation of voltage-sensitive ion channels by guanine 
nucleotide regulatory proteins (G-proteins)
A family of pertussis toxin (IAP) sensitive G-proteins including
Gi , Gi , Gi and Go have been identified in tissues (Falloon 
1 2  3
et al., 1986; Mitchell et al., 1986; Graziano and Gilman, 1987;
Milligan, G., 1988) which when coupled to receptors may translate
external messengers into intracellular responses by directly activating
the voltage-sensitive ion channels instead of the adenylate cyclase.
The brain contains two Gi-type G-proteins, namely Gi^ and Gi^ (Neer
et al., 1984) and it is highly enriched in G (Neer et al.f 1984;
o -------
Sternweis and Robishaw, 1984). Similarly, neuroblastoma-glioma hybrid
cells are also found to contain Gi-type G-proteins and high
concentrations of Go (Milligan et al., 1986).
Electrophysiological techniques including whole cell patch-clamp
recording from dorsal root ganglion (DRG) neurons demonstrate that NA
and y-aminobutyric acid (GABA) inhibitory effect on voltage-dependent
calcium channels are blocked by preincubation of cells with pertussis
toxin (Ui, 1984) or intracellular administration of guanosine
5 ,-0-(2'-thiodiphosphate) (GDP-y-S), a non-hydrolysable analogue of GDP
that competively inhibits the binding of GTP to G-proteins (Eckstein
et al., 1979; Holz et al., 1986). Angiotensin (II) stimulation of 
2+
Ca current in the adrenocortical cell line Y1 (Kojima et al., 1986) 
is abolished in Y1 cells pretreated with pertussis toxin, while
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2 +
mtracellular application of cAMP does not stimulate the Ca current
in the cells. Thus, the finding suggests that G-proteins act as signal
transducers by directly linking the hormones or neurotransmitters to
2+
voltage-sensitive Ca channel independently of cAMP (Fig. 8A).
Sasaki et al. (1987) demonstrated that when hormone receptors
activation of the ganglion cells of the sea slug Aplysia by either
+
acetylcholine (Ach.), histamine or DA leads to an increase in K
conductance, which can be irreversible and selectively blocked by
intracellular injection of pertussis toxin. Furthermore, intracellular
application of guanosine-5'-0-(3-thiotriphosphate) (GTP^y-S), a poorly
hydrolysed analogue of GTP alone, caused extremely slow and irreversible 
+
opening of K channels. This suggests that G-proteins may be
+
involved in the receptor regulation of K channels (Fig. 8B).
+ 2+
K induced depolarization leads to an increase in Ca
      +
influx, which in turn activates K channels causing hyperpolarization
and promoting repolarization (Blatz and Magleby, 1986) thereby switching 
2+
off Ca dependent cellular responses.
2+
1.6.1 Modulation of ion channels by Ca mobilizing receptors
possibly mediated via unknown G-proteins
2+
Occupancy of Ca mobilizing receptors by either adrenaline
( acetycholine (M), substance P, NA ( thyroliberin
(TRH), 5-hydroxytryptamine (5-HT), caenilein or vasopressin (V^)
involve the breakdown of membrane-bound phosphoinositides to a number of
inositol phosphate and diacylglycerol (Taylor and Merritt, 1986).
These reactions are catalysed by phospholipase C. Consequences of the
breakdown of phosphoinositides include mobilization of intracellular 
2+
Ca (Berridge and Irvine, 1984; Taylor, 1987), which in turn may
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activate protein kinase C (Nestler and Greengard, 1983; Hemmings
2+
et al./ 1986). In mast cells, activation of Ca -mobilizing
receptors lead to the stimulation of phospholipase C, the effect of
which is inhibited by pertussis toxin (Nakamara and Ui, 1984).
Similarly, in adipocytes, OC^-adrenergic stimulation of phospholipase C
is inhibited by pertussis toxin, while cholera toxin does not affect the 
2+
coupling of Ca -mobilizing receptors to phospholipase C (Taylor and
Merrit, 1986). The finding suggests that Gs is not involved in this
coupling process. Furthermore, a crude plasma membrane preparation of
blow fly salivary glands produced In(l,4,5)P^ in response to 5-HT only
in the presence of GTP. In addition, stable analogues of GTP, GTP-^-S
and 5 1-guanylylimidodiphosphate [Gpp(NH)p], which stimulate the
formation of Ins(l,4,5)P^ are able to potentiate the effects of 5-HT
(Litosch et al., 1985). The results suggest a close link between an
unknown pertussis toxin sensitive G-protein and phospholipase C. Also,
2+
the increase in intracellular Ca via receptor/G-protein mediated
hormone sensitive phospholipase C may also lead to the activation of
+ 2+
K conductance thereby reducing Ca influx (Fig. 8C).
1.6.2 Modulation of ion channels by intracellular messengers
Protein kinases including cAMP-dependent protein kinase
2+
(cAMP-PK), cGMP-dependent protein kinase (cGMP-PK) and the Ca /
phospholipid-dependent protein kinase (protein kinase C) (PKC) have been
2+
shown to modulate voltage sensitive Ca channels (Rosenthal and
Schultx, 1987; Fig. 8D).
2+
Ca channels of hippocampal neurons are stimulated by cAMP-PK 
(Gray et al., 1987). Electrophysiological studies using the whole cell 
clamp technique demonstrate that intracellularly applied cAMP or the
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2+ +catalytic subunit of cAMP-PK enhances the Ca activated K currents
in snail neurons (Ewald et al., 1985). Similarly, intracellular
infusion of cGMP or of cGMP-PK via patch pipette in snail neurons also 
2+
enhances Ca currents and increases the 5-hydroxytryptamine (5-HT)
2+
induced Ca current (Paupardin-Tristch et al., 1986). Injection of
2+
PKC into mollusc neurons has also been found to enhance Ca currents 
(De Reimer et al., 1985). Nichols et al. (1987) demonstrate that
activation of protein kinase C by tumour-promoting phorbol esters
+ 3 3
enhanced the K -stimulated release of [ H]NA and [ H]Acetycholine
2+
from rat cerebral cortex synaptosomes preparations in a Ca -dependent 
manner. The results suggest that phosphorylation of ion channels by 
protein-kinases may also regulate the release of neurotransmitters.
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Figure 8 Modulation of ion channel activity via cell surface
receptors
(A) G proteins mediate either hormonal stimulation or hormonal 
inhibition of Ca^+ channel activity
(B) Receptor control of K+ channel activity via G-protein
(C) Receptor control of K+ channel activity by an intracellular
messenger
(D) Hormonal modulation of Ca^+ channel activity achieved by
protein kinases including cAMP-PK, cGMP-PK or protein kinase C
Abbreviations: HA, hormonal agonist (hormone or neurotransmitter);
HR, hormone receptor; G, G protein
(From Rosenthal, W. and Schultz, G. (1987) Trends in Pharmacological 
Sciences 8, 351-354.)
)
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1.7 Aim of project
The aim of this project was to examine the hypothesis that 
presynaptic OC^-adrenergic inhibition of noradrenaline release is 
mediated via changes in cAMP formation. This hypothesis is based on 
the observations that CC^-adrenergic agonist in a number of tissues 
have been shown to be linked to the inhibition of cAMP formation.
Answers to the following two questions, relating to this hypothesis were 
sought (i) Does increasing the concentration of cAMP in occipital cortex 
tissue chops reverse the a^-adrenergic inhibition of NA release and
(ii) Is there a relationship between the effect of a^-adrenergic 
agonists on NA release and cAMP formation in rat brain occipital cortex 
tissue chops?
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2. MATERIALS & METHODS
2.1 Materials
Materials used were obtained from the following sources:
Amersham International/ Amersham Buckinghamshire 
3
1— [7,8]— [ H]-Noradrenaline (30-50Ci/mmol)
3
8-[ H]-Adenine (20-25Ci/mmol)
14
U-[ C]-cAMP (261mCi/mmol)
BQC Limited/ Brentford
95% 0 - 5% CO
2 2
Sigma, Poole, U.K.
Noradrenaline
Clonidine
Propranolol
Prazosin
Yohimbine HC1
Isoprenaline
Adenosine
Forskolin
3-Isobutyl-l-methylxanthine
Desipramine
Pargyline
Neutral alumina
Imidazole HC1 
6
N -cyclohexyl adenosine
Ethyleneglycol-bis-(|^-amino-ethyl)N,N'-tetra acetic 
acid (EGTA)
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The a 2_adrener9ic agonists BHT-920 and UK-14304-18 were kindly 
donated by Syntex Research Centre, Riccarton, Edinburgh and Pfizer 
Central Research, Sandwich/ Kent, respectively.
Kindly donated by Dr. D. Pollock/ Department of Pharmacology/ 
University of Glasgow,
Phenylephrine
Kindly donated by Roche Products Ltd., Welwyn Garden City/ 
Hertfordshire 
RO-20-1724 
BDH Chemicals Ltd., Poole, England 
Ascorbic acid 
Folin-Ciocaltean reagent 
Sodium dodecyl sulphate
N-2-Hydroxyethylpiperazine-N-2-ethane sulphonic acid (HEPES) 
BioRad
Dowex AG 50W-X-4; 200-400 mesh (hydrogen form)
Research Biochemical Inc., MA., U.S.A.
8-cyclopentyl-l,3-dipropylxanthine
2.2 Dissection of rat brain
Male Wistar rats (230-250g) were sacrificed by CO^ 
anaesthesia followed by decapitation. Brains were removed and placed 
in a chilled glass petri dish.
For the dissection of occipital cortex, a transverse section 
(Fig. 9 C , dashed line, 1) was made to remove the front brain (A).
The occipital cortex could be easily removed by gently peeling back 
using a spatula beginning at the central ridge (Fig. 9A ). The white 
and grey matter attached to the cortex was removed using forceps. The
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Right
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(A)
Frontal view 
of rat brain
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Ventral view 
of rat brain
Mid-brain+ thalnus LJz
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Coeaisura
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Chiasaa opticua
(C) Saggital section of rat brain, showing the 
diagrammatic representation of dissection 
procedure. Dotted line indicates position 
of initial sections (Glowinski and Iversen, 1966)
Figure 9 Dissection of occipital cortex and hypothalamus
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hypothalamus was dissected out by the method of Glowinski and Iversen, 
1966 (Fig. 9C ). The anterior commissure was taken as a horizontal 
reference and the line between the posterior hypothalamus and the 
mammillary bodies as the caudal limit.
2.3 Preparation of tissue chops
Tissue from occipital cortex or hypothalamus was chopped using
o
a Mcllwain tissue chopper to produce 0.26 x 0.26mm slices cut at 90 
to each other. The tissue chops were then washed once with HEPES
buffer in order to remove tissue debris, and then used for uptake and 
3
release of [ H]NA or for cAMP assay.
2.4 HEPES buffered salines
The HEPES buffer used for both the centrifugation assay and the
cAMP assay consisted of (in millimolar concentrations) : NaCl, 140;
KC1, 5; CaCl , 0.5; HEPES, 15; D-Glucose, 10; K HPO , 1.5;
2 2 4
MgSO .7HO, 1.5; pargyline, 0.1; ascorbic acid, 0.1. The buffer 
4
was equilibrated with 95% °2“5% c°2f anc  ^ pH adjusted to 7.4
o
with 1M NaOH. It was then kept at 4 C. For cAMP assay, pargyline 
and ascorbic acid were omitted from the buffer. High potassium 
concentrations were obtained by replacing NaCl with the equivalent 
amount of KC1 to maintain isomolarity.
2.5 HPLC-ED Assay of endogenous catecholamines from rat brain 
regions
Endogenous NA and DA were assayed by HPLC-ED as shown in 
Figure 10. Brain samples were weighed and then homogenised in 0.5ml 
0.1M PCA in Eppendorf tubes using a mini drill (Expo Drills Ltd.,
- 48 -
London, U.K.) fitted with a teflon-tipped pestle. The tubes were then 
centrifuged at 10,000g for 5 minutes in an Eppendorf 5412 bench 
centrifuge. After that 80ul aliquots of supernatant were injected 
onto a Partisil 10 ODS column (Whatman Ltd., 25cm x 4.6mm i.d.) via a 
six port rotary injection valve (Model 7120, Rheodyne Instruments Ltd., 
U.S.A.) fitted with a 20ul sample loop. A mobile phase of 0.027M 
citric acid, 0.05M sodium acetate, 0.06M sodium hydroxide, pH5.2 
containing 0.057g sodium octyl sulphonate per litre and 2.5% (v/v) 
methanol was used for the separation of catecholamines (Keller et al., 
1976). The mobile phase was filtered through Sartorius filters (0.45m 
pore size) before use, degassed with helium and delivered at a constant 
flow rate of l.lml/min using an LC3-XP pump (Pye Unicam Ltd.,
Cambridge, U.K.). Catecholamines were detected with a TL-5 
electrochemical detector cell (silicon-grease based carbon paste, CP-S, 
Bio-Analytical Systems Incl.) which consisted of a glassy-carbon 
working electrode, Ag/AgCl reference electrode, a platinum auxiliary 
electrode and a LC-4 controller Unit. The operating potential was 
0.65v and the current produced by oxidation of catecholamines was 
transduced by the LC-4 Controller Unit into a peak on a Philips PM8251 
single pen chart recorder (Philips Ltd.). The retention times of NA 
and DA were 4 and 12 minutes respectively. The unknown concentrations 
of NA and DA were calculated from the peak heights produced by the 
samples compared with the peak height produced by standard solutions of
NA and DA (4-20ng/100ul in 0.1M-HC1O ) (Fig. 11).
4
3
2.6 Uptake of [ H]NA into occipital cortex tissue chops
The effect of desipramine (DMI), an uptake inhibitor, on the 
uptake of NA by chopped brain slices was examined using the method of
Heliua
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- 50 -
MOPEG
HVA
T Tr T T T
^ - m i n
Figure 11.
Chromatogram of separation of NA and DA by HPLC 
A) Standard and B) Sample (occipital cortex), Flow 
rate,1.1ml/min; Dopamine (DA) concentration,IOng/20^1; 
Noradrenaline (NA) concentration. 1 0 n g/2Q ul.
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3
2.7 Determination of [ H]NA release
- 7
Tissue chops were prelabelled by incubating with 0.3 x 10 M
3
[ H]NA (specific activity, 30-50Ci/mmol) in HEPES buffer containing 
_ 2+ o
0.5mM Ca for half an hour at 37 C. The tissue chops were then
washed by gently turning the test tube upside down three times,
allowing the tissue to settle and carefully removing the supernatant.
The tissue chops were resuspended in fresh HEPES buffer. This process
2+
was repeated eight times. For the study on Ca dependent release,
tissue chops were washed with HEPES buffer containing O.lmM EGTA,
2+
without Ca . Aliquots (12ul) of the resuspended tissue chops
(5-10mg) were pipetted into Eppendorf tubes using a Gilson pipette with
-6
the tip cut off. 50ul DMI 10 M (final concentrations) was added to
3
each tube to prevent re-uptake of the released*. - [ H]NA. Total
volume in the Eppendorf tube was 0.5ml.
3
Release of [ H]NA was evoked by the addition of 20mM or 30mM
+ o
K and the tubes were incubated for 6 minutes at 37 C either in the
presence or absence of drugs as indicated in the legends of the
+ 2+
relevant figures. For K -evoked Ca -dependent study, different
2+
concentrations of Ca were added to the tubes as mentioned in
legends of the relevant figures. The tubes were shaken at regular
intervals. In some cases, the tissue chops were preincubated for
o
periods up to 30 minutes at 37 C, shaken at regular intervals with
appropriate drugs as indicated in the relevant figures and tables
+
before evoking release with 20mM K as described above. The
reaction was terminated by centrifuging the Eppendorf tubes at 2000 x g 
o
for 5 minutes at 4 C. The supernatant was transferred to vials
containing 4ml "Ecoscint" (liquid scintillant) for scintillation 
3
counting. [ H]NA left in the pellet was extracted by
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Carmichael and Israel (1973). The assay was modified to separate the
labelled tissue from the medium by centrifugation. 12ul aliquots of
the tissue chops (5-10mg) suspended in minimal volume of HEPES buffer
was pipetted into Eppendorf tubes using a Gilson pipette with the tip
-8 -4
cut off. Desipramme (DMI) over the range 10 M-10 M was added
to the tubes except the control, and these were incubated for 10 min at 
o
37 C with regular manual shaking at 2-3 minute intervals. The tubes
o
were then centrifuged for 5 min at 250 x g, at 4 C, and the
supernatant was discarded. After that, fresh medium containing 0.3 x
-7 3
10 M [ H]NA (specific activity, 30-50Ci/mmol) in the presence of
an appropriate dilution of DMI was added to the tubes, which were
o
further incubated for half an hour at 37 C and shaken at regular
intervals. The total volume in the tubes was 0.5ml. The tubes were
o
centrifuged at 2000 x g at 4 C for 5 minutes and the supernatant in
each tube was discarded. The pellets were washed by adding fresh
medium to the tubes, shaking the tubes gently, and allowing the tissues
to settle and the supernatant was discarded. The process was repeated
3
three times. The [ H]NA in the pellet was extracted by homogenising
the tissue with 500ul 0.1M perchloric acid (PCA). The tubes were
o
centrifuged at 2000 x g at 4 C for 5 minutes. The PCA extracts were
transferred into vials containing 4ml "Ecoscint" (scintillation fluid), 
3
and the [ H]NA was determined in a scintillation counter. NA uptake 
was initially expressed as counts per minute (CPM)/mg protein, and then 
converted into % of control value. The protein content of the chopped 
brain slices in the tube was determined by method of Lowry et al. 
(1951).
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homogenisation with 0.5ml 0.1M PCA, and then centrifuged at 2000 x g 
3
for 5 min. The [ H]NA content in the PCA supernatant was determined 
by liquid scintillation counting.
3
2.7.1 Calculation of [ H]NA release 
3
The [ H]NA released under each condition was expressed as:
% of total tissue tritium
= counts per minutes (cpm) supernatant x ^00 
cpm(pellet) + cpm(supernatant)
or s x 100 
P + S
+ 3
The results were expressed as K -induced release of [ H]NA in the
presence or absence of drugs minus the basal (unstimulated) release of 
3
[ H]NA in the presence or absence of drugs.
3
The [ H]NA release expressed as a % of the control value was 
calculated as follows:
[^H]NA release as = % of total tissue tritium in the presence of drugs x 100
% of control % of total tissue tritium
2.8 cAMP assay
cAMP formation in tissue chops was followed by measuring the 
3 3
production of [ H]cAMP from [ H] adenine using the method of Shimizi
o
et al. (1969). Tissue chops were incubated for 15 minutes at 37 C in 
9ml HEPES buffer. The tissue chops were allowed to settle, the
supernatant removed and the tissue chops were incubated for 40 min at
o , -7 3
37 C in fresh medium (9ml) containing 10 M [ H] Adenine (specific
activity 20-25Ci/mmol). The tissue chops were rinsed five times by 
gently shaking the tubes, allowing the tissues to settle, and then 
removing the supernatant. A further incubation of tissue chops with
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fresh HEPES buffered saline was carried out for 10 min at 37°C. The
incubation medium was discarded, and the tissues were suspended in
minimal volume of HEPES buffer. 12ul aliquots of the tissue chops
(5-10mg) were pipetted into Eppendorf tubes using a Gilson pipette with
o
the tip cut off. cAMP formation was stimulated for 10 min at 37 C by 
the addition of isoprenaline, noradrenaline, adenosine, potassium or 
forskolin in the concentrations stated in the relevant figures or 
tables. For the studies with (X^-adrenergic agonist, the tissue chops 
were preincubated with the relevant agonist for 5 minutes before the 
addition of the compound used to stimulate cAMP formation. The reaction
was terminated by centrifuging the tubes for 3 minutes, 2000 x g, at
o 3
4 C. The supernatant was decanted. [ HjcAMP in the tissue pellet
was extracted by homogenisation with 1ml 10% TCA containing 
14
[ C]-AMP(5Ci/100ml 10%.TCA) as internal standard. The Eppendorf
tubes containing 1ml 10% TCA extracts were centrifuged for 10 minutes 
o
2000 x g at 4 C. 50ul of the TCA supernatant was used to determine
3
the total radioactivity in the tissue. [ HjcAMP in the rest of the 
TCA supernatant was then purified using Dowex and alumina columns by
method of Solomon et al. (1974). Results are expressed as percentage
3 ,
conversion; i.e. the percentage of total [ H] adenine taken up by the
3
tissue converted to [ H] cAMP.
2.9 Preparation of Dowex 50 and aluminium columns for adenylate 
cyclase assay (Solomon#1979)
2.9.1 Supplies
(1) Columns used were 5ml syringes, diameter 1 cm, containing a 
sintered filter disk.
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(2) Racks were constructed to hold 24 columns each. They were made 
in such a way that the two columns fitted onto each other in 
pairs, with the columns in the upper and lower racks vertically 
aligned.
(3) The lower columns were properly spaced so that the effluent
3 14
containing [ HjcAMP and [ Cj-AMP could drain into 24
scintillation vials arranged directly below the columns.
2.9.2 Packing Dowex 50 columns
Dowex AG 50W-X4 (200-400 mesh) was placed in a conical flask, 
washed twice with 1M HC1, and equilibrated with 100ml 1M HC1 for 30 
minutes. The acid-treated resin was washed with distilled water until 
the effluent was colour free. Columns were then filled with the resin 
to about 4cm. In order to prevent bacterial and fungal growth, columns 
were stored with 2ml 1M HC1 at room temperature. Columns were washed 
with 10ml distilled water before use.
2.9.3 Packing Alumina Columns
0.6g dry neutral alumina was placed in each column and washed 
with approximately 10ml 1.0M imidazole HC1 buffer, pH 7.5, and stored at 
room temperature. Before use columns were washed with 6ml 0.1M 
imidazole buffer.
2.9.4 Column recycling
Dowex 50 columns; The columns were regenerated by washing with 
4ml 1M HCl, followed by 10ml distilled water.
Alumina columns: Columns were regenerated with 3ml 1M
imidazole/HCl buffer, pH 7.5, followed by 6ml 0.1M imidazole/HCl buffer.
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2.10 cAMP purification
lml TCA extracts of the samples were applied to Dowex columns.
ATP and ADP were eluted with 2.0ml 0.1M HC1, followed by 2.0ml distilled
water. cAMP was then eluted onto the alumina columns with 6ml distilled
water. The alumina columns were washed with lml 0.1M imidazole HC1 and
3
[ HjcAMP eluted with 3.0ml 0.1M imidazole/HCl buffer directly into 
vials containing 12ml Ecoscint.
2.11 Preparation of a dual-label quench curve by external standard 
method
The Beckman LS1800 scintillation spectrophotometer uses a high
137
energy gamma source, such as Cs as an external reference standard
#
and is equipped with the H method for quench correction.
3
The quench curve was calibrated using 10 sealed samples of [ H]
14
or [ C ] of known dpm, supplied by Amersham, containing different
amounts of quenching agent in scintillation fluid. The counting 
3 14
efficiency of [ H ] or [ CJ was then obtained using the formula below:
counting efficiency (CE) = -2HL x 100%
dpm
As a result of this preliminary quench curve, the counter was then
f
programmed to obtain dpm from cpm. H values were set at a minimum of
3 14
39 and a maximum of 219. Counting efficiencies for [ H] and [ C] 
were found to be approximately 40% and 70% respectively.
2.12 Scintillation counting
3
The [ H]NA released was determined by adding in 0.5ml of 
supernatant or 0.5ml of 0.1M PCA tissue extracts to scintillation vial 
containing 4ml Ecoscint, and counted in Beckman LS1800 liquid
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scintillation spectrophotometer for 5 minutes. In the case of cAMP
3 14
assay, radioactivity of [ H]cAMP and [ CjcAMP was counted in larger 
volume of imidazole buffer (3.0ml), therefore it required the use of 12ml 
of Ecoscint to ensure homogeneity.
2.13 Protein estimation
Protein in the tissue pellet was estimated using a modification 
of the method of Lowry et al. (1951) as follows:
(i) Tissue in the pellet was dissolved in 500,ul of 2% (w/v) SDS in
0.1M NaOH overnight, and lOOjal aliquots placed in test tubes.
(ii) To each tube was added 3ml of a mixture of 50ml solution A + lml 
solution B.
Solution A consisted of 2% (w/v) anhydrous Na CO and 0.2%
2 3
(w/v) SDA in 0.1M NaOH, and solution B consisted of 0.5% CuSO
4
5H^O in 1.0% (w/v) trisodium citrate.
(iii) After 10 minutes, 0.5ml Folin-Ciocalteau reagent diluted 1:2
(v/v) with water was added to the tubes, and then mixed with a 
vortex mixer.
(iv) The test tubes were left for at least 30 minutes in order to
allow colour development to stabilize before reading the
absorbance at 650 of the samples using a Beckman Dual Beam
spectrophotometer (Beckman Ltd.).
(v) Protein was estimated by reference to a protein calibration curve
(0-100ug protein) using bovine serum albumin as a standard (Fig. 12).
2.14 Statistical Evaluation
Standard deviation (S.D.) is a measure of the difference of each
- 58 -
0,4
0.3
650
0.2
0.1
0 10 20 30 40 50 90 100
jjg protein
Figure 12 Calibration curve for protein estimation
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observation from the mean. It was calculated using the formula:
SD = (x-x)2
n-1
where,
x = individual observation
x = mean of number of observations
(x-x)2 = sum of the squares of differences
(or deviation from the mean)
n = number of observations
(x~*\ = variance
n-1
Standard errors mean (S.E.M.) was used to describe the 
significance of the difference between the means. It was obtained by 
dividing the S.D. of each sample by the square root of the number of 
observations in the sample (n). It was calculated by using the formula 
below:
S.E.M. — S.D.
I T T
Statistical significance of the effects of two alternative treatments or 
experiments comparing in pairs was determined by the t-test or sometimes 
referred to as Student's t-test. The factor t, the significance of a 
deviation of a statistic from zero was calculated by using the formula: 
t = d —  S «D«.
where,
d = mean of the differences between the two alternative treatments 
= S.E.M. of the differences
>nr
Entering the t value into the table of the t-distribution (Pollard, 197 7) 
at the appropriate degree of freedom gave the probability value of a 
chance effect.
RESULTS
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3.1 Preliminary studies
3.1.1 NA and DA content in the occipital cortex and hypothalamus of 
rat brain
Occipital cortex (O.C.) and hypothalamus were dissected as 
described in the Methods Section. The wet weights of O.C. and
hypothalamus were 37.9 _+ 14.8mg (n = 7, mean +_ S.D.) and 90.1 jf 17.3mg
(n = 7, +_ mean S.D.) respectively.
The NA and DA contents of O.C. and hypothalamus were measured 
using HPLC with electrochemical detection. The NA contents of O.C. 
and hypothalamus were 502 +_ 347ng/g wet weight (n = 7, mean +_ S.D.) and 
1404 +_ 251ng/g wet weight (n = 7, mean +_ S.D.) respectively, while the 
DA contents were 59 _+ 18ng/g wet weight (n = 7, mean _+ S.D.) and
220 Hh 16ng/g wet weight (n = 7, mean +_ S.D.) respectively. Thus both
NA and DA contents in the hypothalamus are,higher than those found in 
the O.C.
3
3.1.2 Effect of desipramine (DMI) on the uptake of [ H]NA in O.C. 
tissue chops
The centrifugation assay used in this study has the advantage
of enabling release to be followed in a small volume, thus economising
on tissue and material. However, the released NA could be rapidly
taken up into the nerve endings, thus reducing the net release of NA.
Therefore, DMI, an inhibitor of NA uptake was included in the assay to
- 6
prevent the re-uptake of released NA. DMI (10 M) inhibited about 
3
90% of [ H]NA uptake (Fig. 13). Thus, this concentration was 
3
included m  all [ H]NA release experiments.
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Figure 13 Effect of DMI on [ H]NA uptake into O.C. tissue chops
Aliquots of tissue chops were preincubated for 10 min at 37 C with
oxygenated HEPES buffer containing DMI. The tissue chops were 
3
loaded with [ H]NA in HEPES buffer containing DMI, range 
-8 -4
(10 M-10 M) for 1/2 h. The total uptake of tissue tritium
-4
averages 10 cmp/mg protein. Protein assay was performed by 
method of Lowry et al. Each point represents the mean +_ S.E.M. of 
4 separate experiments, each of which was performed in triplicate.
- 62 -
3.1.3 _K+-stimulated Ca2+-dependent release of [2H]NA from O.C.
and hypothalamic tissue chops
+ 3
K -evoked release of [ H]NA was examined in O.C. (Fig. 14)
3
and hypothalamic (Fig. 15) tissue chops. Release of [ H]NA increased 
+
with increasing K concentration and reached a maximum over the range
+ +
80mM - 120mM K for both tissues. High K was obtained by
replacing NaCl with the equivalent amount of KC1.
2+ + 3
Ca -dependent K -stimulated release of [ H]NA was
studied in O.C. tissue chops. Figure 16 shows that high K (40mM or
3 2+
20mM) stimulation of [ H]NA is more dependent on Ca
+ + 
concentrations than low K (5mM). The effect of K stimulation on
2+
Ca - dependent release from O.C. tissue chops was examined either in
HEPES buffer equilibrated with 95% 0 - 5% CO and the pH
2 2
subsequently adjusted to 7.4 (Fig.16B) or in non-oxygenated HEPES
+ 3
buffer (Fig. 16A). K stimulation of [ H]NA release is not
dependent on the oxygenation of buffer since very little difference was
observed between maximal release in oxygenated (Fig. 14) compared with
non-oxygenated (Fig. 14) buffer. However, lower basal release was
observed in oxygenated HEPES buffer (Fig. 16A) compared with
non-oxygenated HEPES buffer (Fig. 16B).
3.1.4 Time course of the effect of clonidine on the release of 
3
[ H ]NA from O.C. tissue chops
The effect of clonidine, an CC^-adrenergic agonist, on the
3 +
release of [ H ]NA was studied under depolarizing (30mM K ) and
+
non-depolarizing (5mM K ) conditions by incubating tissue chops with
clonidine (10 ^M) for the different times shown in Figure 17.
-6 3
Clonidine (10 M) did not inhibit the basal release of [ H]NA over
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Figure 14 Effect of K on the release of [ H]NA from O.C.
tissue chops
3 3
Tissue chops were preloaded with [ H]NA. Release of [ H]NA was
evoked by incubating the tissue chops with different K+
concentrations as shown above either in non-oxygenated (A ) or
oxygenated (95% 0^ - 5% (O) HEPES buffer medium containing
-6 o
10 M DMI for 6 min at 37 C. Each point is the mean of 5
experiments _+ S.E.M., each of which was performed in triplicate.
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Figure 15 Effect of K on the release of [ H]NA from rat
hypothalamic tissue chops
3 3
Tissue chops were preloaded with [ H]NA. Release of [ H]NA was
evoked by incubation of tissue chops under the conditions described
in Fig. 14. Results are means _+ S.E.M. of 4 experiments, each of
which was performed in triplicate.
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2+ +Figure 16 Effect of Ca -dependent K -evoked release of
3
_[_ H]NA from O.C. tissue chops
3
Tissue chops were preloaded with [ H]NA under two conditions
(A) non-oxygenated or (B) oxygenated HEPES buffer. Tissue chops were
2+
then washed with HEPES buffer without Ca containing O.lmM EGTA
according to the conditions in (A) and (B) respectively. 5mM (• ),
+ 3
20mM (□) and 40mM ( O )  K -evoked release of [ H ]NA in the
2+
presence of different Ca concentrations described above were 
performed under conditions described in Fig.14. Results are means 
+_ S.E.M. of 4 experiments.
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+
a 15 min incubation period,while it inhibited 30mM K -evoked release 
3
of [ H ]NA at all time points (Fig. 17). The above observation
+ 3
suggests that clonidine inhibition of K -evoked release of [ H]NA
was an instantaneous effect, and remained effective over the time range.
3.1.5 Effect of pretreatment of tissue chops with clonidine on
+ 3K -evoked release of [ H]NA from O.C. tissue chops
-6
Clonidine (10 M) added to the incubation tube at the same
+ 3
time as 30mM K inhibited release of [ H]NA from O.C. tissue chops
by 40.% (Fig. 18A). Pretreatment of tissue chops with clonidine for 10
min (Fig. 18B), 20 min (Fig. 18C) or 30 min (Fig. 18D) at 37°C before
3 + o
evoking [ H]NA release with 30mM K for 6 min at 37 C did not
3
alter the extent to which clonidine inhibited [ H]NA release. These
results show that it is not necessary to pretreat the tissue chops with
3
clonidine to obtain maximum inhibition of [ H]NA release.
+
3.1.6 Effect of clonidine on 40mM, 30mM and 20mM K -evoked release 
3
of [ H 3NA from O.C. tissue chops
+ 3
The effect of clonidine on K -evoked release of [ H]NA was
investigated either in non-oxygenated (Fig. 19A) or oxygenated (Fig. 19B)
+ 3
HEPES buffer medium. K -evoked release of [ H]NA was expressed as
the difference between percentage release in the presence of 40mM, 30mM
or 20mM KC1 and 5mM KC1. When the experiment was performed in
-6
non-oxygenated HEPES buffer medium, clonidine (10 M) did not inhibit
+ 3
40mM K -stimulated release of [ H]NA, while only 20.6% and 33.1%
inhibition were observed at 30mM and 20mM K+ respectively (Fig. 19A).
However, when the experiment was performed in oxygenated HEPES buffer
-6 + 
medium, clonidine (10 M) inhibited 40mM, 30mM and 20mM K -evoked
3
release of [ H ]NA by 17.1%, 37.3% and 52.5% respectively (Fig. 19B).
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Figure 17 Effect of clonidine on [ H]NA released from O.C.tissue chops
Time course study
3
Aliquots of tissue chops preloaded with [ H]NA were incubated in 
oxygenated (95% 0^ - 5% CO^) HEPES buffer for up to 15 min either in
the presence ( B  , •  ) or absence (□, O  ) of 1 lpM clonidine with either
4- 4-
5mM K (B, □  ) or 30mM K (•, O  ). Results are means 4- S.E.M. of
3 experiments.
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The above observations show that oxygenation of HEPES buffer medium is
prerequisite to a better clonidine inhibition, and that lower
+ +
K -depolarization (20mM K ) gave a greater extent of clonidine
inhibition. Therefore, oxygenated HEPES buffer was used in all the
3
experiments on C^-adrenergic regulation of [ H]NA release.
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+ 3Figure 18 Effect of clonidine on K stimulated [ HjNA release
from O.C. tissue chops under different preincubation 
conditions
3
Tissue chops were preloaded with [ H]NA. The experiments were
carried out under four conditions: (A) No preincubation, (B) 10 min,
(C) 20 min and (D) 30 min preincubation of tissue chops with lpM
- 4* 3
clonidine. 5mM (^) or 30mM ([J) K -evoked release of [ H]NA
either in the presence or absence of lpM clonidine for 6 min . Results 
are means + S.E.M. of 3 experiments.
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Figure 19 Inhibitory effect of clonidine on 40mM, 30mM and 20mM
K +-evoked release of [ ^HjNA from O.C tissue chops
Aliquots of tissue chops preloaded with [ H]NA in either
(A) non-oxygenated, or (B) oxygenated (95%)2-5%CC>2) HEPES buffer.
+ 3 ujsjK -evoked release of [ H]NA either in the presence (g|j) or
absence ( □ >  of lpM clonidine described in (A) and (B) was examined by
incubating the tissue chops for 6 min. Results are means _+ S.E.M. of
5 experiments.
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3.2 a  adrenergic regulation of [ H]NA release
The results from the preliminary studies show that the
3
a 2~adrenergic agonist, clonidine inhibits [ H]NA release 
+
stimulated by K from rat O.C. tissue chops. Ot ^ -Adrenergic
agonists have been reported to inhibit cAMP formation in a number of
tissues, including human (Burns et al., 1982) and hamster adipocytes 
(Garcia-Sainz et al., 1980) mouse Neuroblastoma X glioma cells, NG 108 
- 15 cells (Sabol and Nirenberg, 1979), and cultures of astrocytes 
derived from mouse (Van Calker et al., 1978) and rat brain (McCarthy et
al., 1979), thus the major aim of this study was to test the hypothesis
that the (X^-adrenergic agonist inhibition of NA release is mediated 
by cAMP. Two approaches were adopted in the study:
(1) If the (^-adrenergic agonist inhibition of NA release is 
mediated by cAMP then it would be predicted that increasing 
intracellular cAMP levels would (a) stimulate NA release and 
(b) reverse the inhibitory effect of the a^-adrenergic 
agonist. Therefore intracellular levels of cAMP were increased 
using the cAMP analogue db-cAMP, Forskolin, (which is known to 
alter intracellular cAMP levels) and with PDE inhibitors, that 
prevent the breakdown of cAMP.
(2) The effect of c^-adrenergic agonists on cAMP formation in 
O.C. tissue chops was examined to see if there is a correlation 
between conditions under which oc^-adrenergic agonists 
inhibit both cAMP formation, and the release of NA.
In this thesis the effects of o^-adrenergic agonists,
clonidine, BHT-920 and UK143-4-18 were compared with the effects of NA,
3
on both release of [ H]NA, and cAMP formation in rat O.C. tissue 
chops.
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■f 3
3.2.1 (X^-adrenergic modulation of K -evoked release of [ H]NA
from O.C. and hypothalamic tissue chops
BHT-920, clonidine, UK14304-18 and NA inhibited the release of
+ 3
20mM K -evoked release of [ H]NA in a dose-dependent manner
+ 3
(Fig. 20). 20mM K was used to stimulate ( H]NA release in O.C.
tissue chops since it was found (Fig. 19) that clonidine was most 
effective at this concentration. The IC values (concentration of
59
drug which exhibits half the maximum inhibitory effect) on the release
3 -7 -7 -7
of [ H]NA) were 1 x 10 M, 3.5 x 10 M, 5.5 x 10 M and
-7
7.5 x 10 M for UK14304-18, clonidine, BHT-920 and NA respectively
(Fig. 20). This suggests a potency order of UK14304-18'>* clonidine>-
^  3
BHT-920 NA. Maximum inhibition of the release of [ H]NA was
-5
achieved by a 10 M concentration of each a 2~agonist. NA was the
+ 3
most effective as it inhibited 20mM K -evoked release of [ H]NA by
about 84%, compared with 70%, 53% and 37% inhibition achieved by
UK14304-18, clonidine and BHT-920 respectively (Fig. 20). On the
-5
contrary, yohimbine (10 M), an (^-adrenergic antagonist, enhanced
+ 3
20mM K -stimulated release of [ H]NA by 25% (Fig. 20).
+
Clonidine and NA also inhibited the 30mM K stimulated 
3
release of [ H]NA from hypothalamic tissue chops (Fig. 21). Unlike
3
O.C. tissue chops, maximum inhibition of [ H]NA release was not 
-4
reached by 10 M concentration for both NA and clonidine. Clonidine
+
and NA had the same inhibitory effect on 30mM K -evoked release of
3 -6 -7
[ H]NA at submicromolar (10 M - 10 M) concentrations.
-4 -4
However, NA (10 M) was more effective than clonidine (10 M) as it
+ 3
inhibited K -stimulation of [ H]NA release by 60% compared with an
inhibition of 40% observed with clonidine (Fig. 21). On the contrary,
-5 3
yohimbine (10 M) only slightly enhanced [ H]NA release (Fig. 21).
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Figure 20 Dose response curves forC^-adrenergic agonists and
antagonist (yohimbine) on the release of [ ]NA from 
O »C. tissue chops
3
Aliquots of tissue chops preloaded with [ H]NA were stimulated 
+
with 20mM K in the presence of C^-agonist, BHT-920 (■),
clonidine (□), UK14304-18 (A.) and NA ( A)  or (X -antagonist,
2
yohimbine ( O)  for 6 min. Control release was 9.6 _+ 0.5% of total 
tissue tritium. Results are means _+ S.E.M. of 4 experiments.
Each was performed in triplicate.
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Figure 21 Dose response curves for PC -adrenergic agonists and
3
antagonist on the release of [ H]NA from hypothalamic 
tissue chops
Aliquots of tissue chops preloaded with [ H]NA were stimulated with 
+
30mM K in the presence of OC2~adrenergic agonist, clonidine ( O)  or
NA (• ) or OC^-adrenergic antagonist, yohimbine ( A)  for 6 min.
Control release was 16.8 +_ 0.45% of total tissue tritium. Results are 
means + S.E.M. for 4 experiments.
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The above observations suggest that O.C. tissue chops is a
better system to use in the study of ot^a^enoceptors regulation of 
3
[ H]NA release since more potent inhibitions by 0C2-adrenergic 
agonists are observed.
3
3.2.2 The effect of yohimbine on the inhibition of [ H]NA 
release from O.C. and hypothalamic tissue chops by 
OC^-adrenergic agonists
+ 3
The mhibiton of 20mM K -evoked release of [ H]NA from O.C.
-6
tissue chops by a 2-a^rener9ic agonists (10 M), BHT-920, NA,
clonidine and UK14304-18 were reversed by the (X^-adrenergic
antagonist, yohimbine, in a dose-dependent manner (Fig. 22). Complete
-5
reversal of inhibition was achieved by yohimbine (10 M). In
contrast, neither the p _a<3rener9^c antagonist propranolol (Fig. 23)
nor a^-adrenergic antagonist prazosin (Fig. 24 ) reversed the
+ 3
inhibitory effect of NA on K stimulation of [ H]NA release from
O.C. tissue chops. This suggests that the inhibitory effect of NA on
+ 3
K -stimulation of [ H]NA release is mediated by a^adrenergic
-6
receptors. Interestingly, in the presence of propranolol at 10 M
-5 -6
or 10 M concentration, the inhibitory effect of NA (10 M) on
+ 3
K -stimulation of [ H]NA released was increased (Fig. 23). The
+ 3
inhibition of K -stimulation of [ H]NA released by clonidine
-5
(10 M) in hypothalamic tissue chops was also reversed by yohimbine 
(Fig. 25 ).
+
3.2.3 Effect of preincubation with forskolin on K -evoked release 
3
of [ H]NA from O.C. tissue chops
-5
Premcubation of tissue chops with 10 M forskolin for 30 min
+ 3
enhances K -evoked release of [ H]NA by 26.7% (Table 3). On the
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120-1 i 10 M Agonist
[Yohimbine] M
Figure 22 Reversal effect of OC^-adrenergic antagonist (yohimbine)
on PC -adrenergic agonist inhibitory response on
+ 3K -evoked release of [ H]NA from O.C tissue chops
Aliquots of tissue chops preloaded with [ H]NA were stimulated
+  —  6
with 20mM K in the presence of 10 OC2-adrenergic agonist,
NA ( O ) ,  clonidine (•), UK14304-18 ( A )  or BHT-920 (▲ ) and
increasing concentration of yohimbine for 6 min. Control release
was 9.8 _+ 0.3% of total tissue tritium. Results are means _+ S.E.M.
of 4 experiments, each of which was performed in triplicate.
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Figure 23 Effect of ^-adrenergic antagonist (propranolol) on the
inhibitory response of NA on K+-evoked release from 
O.C. tissue chops
3
Aliquots of tissue chops preloaded with [ H]NA were stimulated
+  - 6
with 20mM K in the presence of 10 M NA with increasing
concentrations of propranolol for 6 min. Control release was
10.2 hp 0.5% of total tissue tritium. Results are means _+ S.E.M.
of 4 experiments.
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Figure 24 Effect of a  -adrenergic antagonist (prazosin) on the
+
inhibitory response of NA on K -evoked release of 
[ ]NA from O.C. tissue chops
Aliquots of tissue chops preloaded with [ H]NA were stimulated with
+  —  6 
20mM K in the presence of 10 M NA and increasing concentration
of prazosin for 6 min. Control release was 9.3 _+ 60% of total tissue 
tritium. Results are means _+ S.E.M. of 3 experiments.
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Figure 25 Effect of yohimbine on clonidine inhibition of K +-evoked
3
release of [ H]NA from hypothalamic tissue chops
3 3
Tissue chops were preloaded with [ H]NA. Release of [ H]NA from
hypothalamic tissue chops was stimulated by 30mM K+ under condition
described in Fig. 22. Control release was 15.2 _+ 0.38% of total
tissue tritium. Results are means ±  S.E.M. of 3 experiments.
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contrary, only 18.0% enhancement of stimulated release was observed if 
the tissue chops were incubated with forskolin for 15 min, while 5.6% 
was observed if forskolin was added without preincubation (Table 3 ).
This suggests that increases in intracellular cAMP stimulate release 
since forskolin has been shown to stimulate adenylate cyclase by acting 
on the catalytic unit (Seamon and Daly, 1980; Seamon et al., 1981; 
and Daly et al., 1982).
3.2.4 Effect of db-cAMP, forskolin and PDE-inhibitors (IBMX and
RQ20-1724) on OC^-adrenergic agonist modulation of
+ 3
K_ -evoked release of [ H]NA from O.C. tissue chops
3 +
Stimulation of [ H]NA release by 20mM K was also increased
-3 -4
by 28.2% (Table 4) even when db-cAMP (10 M) and IBMX (10 M) were
added without preincubation. These concentrations of db-cAMP and IBMX
+ 3
did not affect clonidine inhibition of K stimulation of [ H]NA
release under these conditions. Preincubation of tissue chops with
-4 -3 -5
IBMX (10 M), db-cAMP (10 M) and forskolin (10 M) for 30
+ 3
minutes enhanced K -evoked release of [ H]NA by 19.0%, 29.0% and
20.8% respectively (Table 5). in addition db-cAMP was capable of
— 6 + 
partially reversing clonidine (10 M) inhibition of K -evoked
3
release of [ H]NA (Table 5).
-4 + 3
In the presence of IBMX (10 M) K stimulation of [ H]NA
release by forskolin and db-cAMP was enhanced. Under these conditions
3
only db-cAMP was able to partially reverse the inhibiton of [ H]NA
release by the c^-adrenergic agonists clonidine, BHT-920, UK14304-18
3
and NA (Table 6). No reversal of [ H]NA release could be observed
-4
when tissue chops were preincubated for 30 min with IBMX (10 M) and 
-5
forskolin (10 M) (Table 6). On the contrary, db-cAMP and forskolin in the
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Table 3 Effect of forskolin on [ H]NA release at various 
preincubation time from the O.C. tissue chops
Condition %[3H]NA released 
+ S.E.M.
% Enhancement of 
[3H]NA released
(a) No preincubation 
Control 7 . 2 + 0 . 6 1  -
Forskolin 7.6 + 0.81 5.6
(b) 15 min preincubation 
Control 8.8 + 0.09, b 1
Forskolin . 10.4 + 0.79, b 18.2
(c) 30 min precinubation 
Control 8.6 ±  0.22, c'
Forskolin 10.9 ±  0.25, c 26.7
3 -5
Tissue chops preloaded with [ H]NA were treated with 10 M forskolin 
under the following conditions: (a) without preincubation; (b) 15 min
precubation and (c) 30 min preincubation, before stimulating release with
+
20mM K for 6 min. Enhancement of release is expressed to their
relative control. results are means _+ S.E.M. of 6 experiments.
k Significantly different from control b 1 0.05)
c Significantly different from control c 1 (p<0.01)
Table 4 Influence of IBMX, db-cAMP and clonidine (without pretreatment
of tissue chops with IBMX and db-cAMP) on K+ stimulation of •
3
[ H ]NA released from O.C. tissue chops
Preincubation % of [3H]NA % Inhibition of % Enhancement of
condition released +_ S.E.M. [3H]NA released [3H]NA released
None (control 7.8 + 0.49
Clonidine 4.9 + 1.67 37.2
db-cAMP + IBMX 10.0 +_ 0.20, a 28.2
db-cAMP + IBMX
+ clonidine 5.7 + 2.25 43.0
-4 -3 -6
10 M IBMX, 10 M db-cAMP and 10 M clonidine were added to
3
aliquots of tissue chops preloaded with [ H]NA and stimulated with 20mM 
+
K for 6 min. Data is expressed as the difference between % release
+ +
in the presence of 20mM K and 5mM K . Results are means _+ S.E.M. 
of 6 experiments.
Significantly different from control (p<0.05)
Table 5 Effect of forskolin, db-cAMPr IBMX and clonidine on the release 
3
of [ H]NA from O.C. tissue chops
Preincubation
condition
% of [3 
released 
(n)
H ]NA 
±  S.E. M.
% Inhibition of 
[3H]NA released
% Enhancement of 
[3H]NA released
condition 10.1 + 0.50 (10)
clonidine 4.6 _+ 0.30 (10) 54.5, b
IBMX 12.0 + 0.28 (8) 19.0
IBMX+clonidine 5.7 + 0.49 (8) 52.5
forskolin 12.2 + 0.20 (5) 20.8
forskolin + 5.1 + 0.15 (5) 58.2
clonidine
db-cAMP 13.0 +_ 0.50 (5) 29.0
db-cAMP + 8.0 0.20 (5) 38.5, a
clonidine
3 -4
Tissue chops preloaded with [ H]NA were preincubated with 10 M IBMX,
-3 -5 „
10 M db-cAMP or .10 M forskolin for 30 m m .  Release was stimulated
+
by 20mM K either in the presence or absence of clonidine for 6 min,
and is expressed as the mean +_ S.E.M. of (n) experiments, of the
+
difference between percentage release in the presence of 20mM K and 
+
5mM K . Enhancement of release is expressed relative to control. 
Inhibition of release is expressed relative to the respective condition 
in the absence of clonidine.
Significantly different from b (p <  0.01)
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Table 6 Effect of forskolin or db-cAMP in the presence of IBMX
on 0t9-adrenergic agonist regulation of [3H]NA release from 
O.C. tissue chops
Preincubation % of [3H]NA % Inhibition of % Enhancement of
condition released + S.E. 
(n)
M. [3H]NA released [3H]NA released
control 10.1 +_ 0.50 (10)
clonidine 4.5 + 0.24 (10) 55.4, a*
BHT-920 7.1 + 0.46 (6) 29.7, b*
UK 14304-18 4.1 + 0.34 (6) 59.4, c*
NA 5.7 +_ 0.49 (6) 43.6, d*
IBMX + forskolin 13.2 ±  0.39 (4) 30.7
IBMX + forskolin 
+ clonidine 6.2 +_ 0.50 (4) 53.0
IBMX + forskolin 
+ BHT-920 10.0 +_ 0.33 (4) 24. 2
IBMX + forskolin 
+ UK 14304 6.0 + 0.36 54.5
IBMX + forskolin 
+ NA 8.1 + 0.32 (4) 39.0
IBMX + db-cAMP 14.6 + 0 . 6 (6) 40.0
IBMX + db-cAMP 
+ clonidine 9.4 + 0.5 (6) 33.3, a
IBMX + db-cAMP 
+ BHT-920 11.7 ±  0.21 (4) 17.0, b
IBMX + db-cAMP 
+ UK 14304-18 8.8 + 0.30 (4) 37.6, c
IBMX + db-cAMP 
+ NA 9.7 + 0.20 (4) 31.2, d
Tissue chops preloaded with [3H]NA were preincubated alone or with 
10”3M db-cAMP or lCT^M forskolin in the presence of 10“^M IBMX for 
30 min. Release was stimulated by 20mM K+ either in the presence or 
absence 10“^M C^-adrenergic agonist for 6 min. Results are means 
Hh S.E.M. of (n) experiments. Enhancement of release is expressed 
relative to control. Inhibition of release is expressed relative to the 
respective condition in the absence of O^-adrenergic agonist.
a, b, c and d significantly different from a*, b*, c* and d* respectively 
(p ^  0.01)
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+ 3
presence of RO 20-1724 neither enhanced K -evoked release of [ H]NA
nor partially reverse the inhibition caused by UK 14304-18 (Table 7).
3.2.5 Influence of db-cAMP and forskolin in the presence of IBMX on
+
clonidine inhibitory response of K -evoked release of 
3_L H]NA from hypothalamic tissue chops
Preincubation of hypothalamic tissue chops with either db-cAMP
-3 -4 -5 -4
(10 M) and IBMX (10 M) or forskolin (10 M) and IBMX (10 M)
gave rise to a slight enhancement of about 7.0% each on 30mM
+ 3
K -evoked release of [ H]NA (Table 8a). Similarly, a 25%
3
enhancement of [ H ]NA release was observed when the release of 
3 +
[ H]NA was stimulated with 25mM K following the preincubation of
hypothalamic tissue chops with db-cAMP or forskolin in the presence of
-4 -5 +
IBMX (10 M). Clonidine (10 M) inhibited 25mM K -evoked
3 +
release of [ H]NA by 37.3% (Table 8B) and 30mM K -evoked release of
3
[ H ]NA by 30.0% (Table 8A). Preincubation of hypothalamic tissue
chops for 30 min with either db-cAMP or forskolin in the presence of
+
IBMX did not reverse clonidine inhibiton of K -evoked release of 
3
[ H]NA release (Table 8a, B). The failure of db-cAMP in the 
presence of IBMX to partially reverse clonidine inhibition of NA 
release represents a difference between hypothalmus and occipital 
cortex tissue chops.
3.2.6 Effects of adenosine and cyclohexyl-adenosine (CHA) on the
3
release of [ HjNA from O.C. tissue chops
+ 3
Adenosine inhibited 20mM K -evoked release of [ H]NA in a
-9
dose-dependent manner (Fig. 26), with an IC_. value of 6 x 10 M.
5U
+ 3
Maximum inhibition of 20-30% of K -stimulated release of [ H]NA was
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Table 7 Effect of forskolin or db-cAMP in the presence of RO 20-1724 on
UK 14304-18 regulation of
3
[ H]NA release from O.C. tissue
chops
Preincubation % of
3
[ H ]NA % Inhibition of
condition released _+ S.E. M. (n)
3
[ H]NA released
control 10.1 + 0.5 (10)
UK 14304-18 4.1 + 0. 34 (6) 59.4
RO 20-1724 8.2 + 0.60 (5) 18.8
RO 20-1724 + UK 14304-18 3.6 + 0.46 (5) 56.1
RO 20-1724 + db-cAMP 9.6 + 0.90 (5)
RO 20-1724 + db-cAMP
+ UK 14304-18
4.5 ±  0.42 (5)
53.1
RO 20-1724 + forskolin 10.8 + 0.33 (5)
RO 20-1724 + forskolin
+ UK 14304-18
4.8 + 0.48 (5) 55.6
Tissue chops with [ H]NA were preincubated alone or with 10 M
-5 -4
db-cAMP or 10 M forskolin in the presence of 10 M RO 20-1724 for
+
30 min. Release was stimulated by 20mM K either in the presence or 
-6
absence 10 M UK 14304-18 for 6 min. Results are means +_ S.E.M. of 
(n) experiments. Inhibition of release is expressed relative to the 
respective conditions in the absence of UK 14304-18.
-  8 7  -
Table 8A, B Effect of db-cAMP, forskolin and clonidine on K+-evoked 
release of [^HjNA from hypothalamic tissue chops
Table A 30mM K+ stimulation of [^H]NA released
Preincubation % of [^H]NA % Inhibition of % Enhancement of
condition released + S.E.M. [^H]NA released [^H]NA released
None (control) 17.7 +_ 0.21
clonidine 12.4 + 0.68 30.0
IBMX + db-cAMP 19.0 + 0.36, a 7.3
IBMX + forskolin 18.9 + 0.89, a 6.8
IBMX + db-cAMP 
+ clonidine 13.4 Hh 1.04 29.5
IBMX + forskolin 
+ clonidine 12.5 + 0.56 33.9
a Significantly different from control (p^ 0.05) 
Table B 25mM K+ stimulation of [^H]NA released
Preincubation % of [ ]NA % Inhibition of % Enhancement of
condition released + S.E.M. [^H]NA released [^H]NA released
None (control 11.0 +_ 0.47
clonidine 6.9 + 0.57
IBMX + db-cAMP 13.8 +_ 0.57, b
IBMX + forskolin 13.6 + 0.61, b
IBMX + db-cAMP 
+ clonidine 8.7 + 0.18
IBMX + forskolin 
+ clonidine ^.7 —  0*19 43.4
k Signifcantly different from control (p*C0.05)
3
Aliqots of tissue chops previously preloaded with [ H]NA were
-3 -5
preincubated either alone or with 10 M db-cAMP or 10 M forskolin in
-4 o
the presence of 10 IBMX for 30 min at 37 C. Release was affected
+ + 
with either 30mM K (Table A) or 25mM K (Table B) in the absence or
-5
presence of 10 M clonidine for 6 min. Results are means + of 6 
experiments.
-  8 8  -
achieved by 10 M adenosine. CHA which is more potent as an A^
+ 3
than A2 agonist, also inhibited the K -stimulation of [ H]NA
release in a dose-dependent manner (Fig. 26), with an value of 8
-10 + 
x 10 M. Maximum inhibition of 40% of K -stimulated release of
3 -6
[ H]NA was achieved by 10 M CHA. This suggests that CHA is more
3
potent and effective than adenosine in inhibiting [ H]NA release.
Slight reversal of inhibition was observed with higher concentrations
-5 -4
(10 -10 M) of CHA.
3.2.7 Effects of PDE-inhibitors, IBMX and RQ20-1724 on the adenosine
3
inhibitory response of [ H]NA release from O.C. tissue chops
-6 -4 %
IBMX (10 M - 10 M) did not affect the 20mM
+ 3
K -stimulated release of ( H]NA (Fig. 27B). However, this
concentration range of IBMX reversed the inhibition of 20mM 
■ + 3 -6
K -stimulated release of [ HjNA caused by 10 M adenosine (Fig. 27A)
-4 -6
IBMX (10 M) in the presence of adenosine (10 M) enhanced the
+ 3
K -stimulated release of [ H]NA by about 15% (Fig. 27A). This
observation is in agreement with reports that IBMX acts as an adenosine
antagonist as well as a PDE inhibitor. This suggestion is supported
by the observation that RO 20-1724, a PDE-inhibitor which does not act
as an adenosine receptor antagonist did not reverse the inhibitory
-6 + 3
effect of 10 M adenosine on K -stimulation of [ H]NA release
(Fig. 28A).
3.2.8 Effect of adenosine A^ antagonist, CPDPX on adenosine inhibitory
+ 3
response of K -evoked release of [ H]NA from O.C. tissue chops
-7 -5
8-Cyclopentyl-l,3-dipropylxanthine, CPDPX (10 M - 10 M),
which is approximately 150 times more selective as an A^ than A^
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Figure 26 Dose response curves for adenosine and cyclohexyl-adenosine
3
(CHA) on the release of [ H]NA from O.C. tissue chops
3
Aliquots of tissue chops preloaded with [ H]NA were stimulated with
20mM K either in the presence of adenosine (6 ) or CHA ( O )  for
6 min. Control release was 9.2 +_ 0.5% of total tissue tritium.
Results are means _+ S.E.M. of 4 experiments.
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Figure 27 Effect of IBMX on the inhibitory response of adenosine on
+ 3
_K -evoked release of [ H]NA from O.C. tissue chops .
Aliquots of tissue chops preloaded with [ H]NA were stimulated with
+  —  6 
20mM K in the presence of 10 M adenosine with increasing
concentration of IBMX (© ) or IBMX alone ( O)  for 6 min Control
release was 9.8 _+ 0.28 % of total tissue tritium. Results are means
_+ S.E.M. of 3 experiments.
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Figure 28 Effect of RO 20-1724 on the inhibitory response of
+ 3
adenosine on K -evoked release of [ H]NA from 0. C.
tissue chops
Aliquots of tissue chops preloaded with [ H]NA were stimulated with
+  —  6 
20mM K in the presence of 10 M adenosine with increasing
concentration of RO 20-1724 (• ) or RO 20-1724 alone ( O  ) for 6 min
Control release was 10.5 +_ 0.25% of total tissue tritium. Results
are means + S.E.M. of 3 experiments.
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antagonist (Martinson et al., 1987), reversed the inhibition of 20mM
+ 3 - 6
K -stimulated release of [ H]NA caused by 10 M adenosine
-5
(Fig. 29A). Furthermore, CPDPX (10 M) in the presence of adenosine
-6 + 3
(10 M) enhanced the K -evoked release of [ H]NA by about 10%
-4
(Fig. 29A), as was also observed with IBMX (10 M) (Fig.27A).
+ 3
3.2.9 NA and adenosine modulation of K -evoked release of [ H]NA
from O.C. tissue chops
-6 .-6 ... +
NA (10 M) and adenosine (10 M) inhibited 20mM K -evoked
3
release of [ H]NA by 40% and 20% respectively (Fig.30 ). The
-5
OC^-adrenergic antagonist, yohimbine, at a concentration of 10 M,
+
slightly reduced the adenosine inhibition of K -stimulation of 
3
[ H]NA release, while it was able to completely reverse the NA
+ 3
inhibition of K -stimulation of [ H ]NA release (Fig. 30). On the
-4
contrary, the adenosine antagonist, 10 M IBMX, did not affect NA
+ 3
inhibition of K -evoked release of [ H]NA, while it was able to
+
completely reverse the adenosine inhibition of K -stimulation of 
3
[ H]NA release. The partial reversal of adenosine inhibition by
yohimbine suggests that a^-adrenoceptors may also play a regulatory
3
role in adenosine effect of [ H]NA release.
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Figure 29 Effect of CPDPX on the inhibitory response of adenosine
+ 3
on K -evoked release of [ HJNA from O.C. tissue chops
Aliquots of tissue chops preloaded with [ H]NA were stimulated with 
+
20mM K in the presence of adenosine with increasing concentration 
of CPDPX ( •  ) or CPDPX alone (O  ) for 6 min. Control release was 
T0.5 +_ 0.30% of total tissue tritium. Results are means _+ S.E.M. of. 
3 experiments.
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Figure 30 NA and adenosine modulation of K+-evoked release of 
3
J_ H ]NA in O.C. tissue chops 
3
Tissue chops preloaded with [ H]NA were stimulated with either 20mM 
K+ alone (O) or in the presence of adenosine (|§) or NA (§§) with or 
without yohimbine (YOH) or IBMX as indicated on the figure for 6 min. 
Results are means _+ S.E.M. of 4 separate experiments.
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3.3 Regulation of cAMP formation in O.C. tissue chops
3.3.1 Stimulation of cAMP formation by forskolin, NA and isoprenaline
in the absence or presence of IBMX and RO 20-1724
Forskolin, NA and isoprenaline stimulated cAMP formation in
O.C. tissue chops (Fig. 31) with EC values (i.e. concentration of
50
-6
drug which stimulates half maximal cAMP formation) of 5 x 10 M,
-6 -9
4 x 10 M and 55 x 10 M respectively. Maximum responses were
-4 -5 -4
achieved by 10 M forskolin, 10 M NA and 10 M isoprenaline,
with 5-9 fold, 2-3 fold and 1.5 fold stimulations being observed
respectively.
-4
IBMX (10 M) had no effect on either the potency or efficacy
of forskolin to stimulate cAMP formation. Thus the inclusion of a
PDE-inhibitor did not affect forskolin stimulation. On the contrary,
NA and isoprenaline no longer stimulated cAMP formation in the presence
of IBMX (Fig. 32). These observations were unexpected since the
inclusion of a PDE-inhibitor would be expected to enhance, rather than
-4
inhibit cAMP formation. Interestingly, 10 M RO 20-1724 although
elevating the basal levels, did not affect the EC values of
50
forskolin, NA and isoprenaline stimulation of cAMP formation (Fig. 33).
3.3.1.1 Effects of CX and {5 -adrenergic antagonists on NA or
isoprenaline stimulation of cAMP formation
The a t a 2 and p-adrenergic antagonists prazosin,
-5
yohimbine and propranolol blocked the NA (10 M) stimulation of cAMP
formation in O.C. tissue chops in a concentration dependent manner
—9 —8 —8
(Fig. 34) with IC_n values of 6 x 10 M, 10 M and 3 x 10 M 
5U
respectively. This suggests a potency order of prazosin>  yohimbines
-5
propranolol. At 10 M concentrations, prazosin, yohimbine and
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Figure 31 Dose response curves of forskolin/ NA and isoprenaline
3
stimulation of [ HjcAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with 
forskolin (•), NA ( O)  and isoprenaline ( A)  for 10 min. Results 
are means +_ S.E.M. of 6 experiments
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Figure 32 Influence of IBMX on dose response curves of forskolin,
3NA and isoprenaline stimulation of [ HjcAMP formation 
in O.C, tissue chops
Tissue chops were labelled with [ H] adenine then incubated with
forskolin ( O ) ,  NA (•) and isoprenaline (A) in the presence of 
-4
10 M IBMX for 10 min. Results are means + S.E.M. of 3 experiments.
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Figure 33 Influence of RO 20-1724 on dose response curves of
3
forskolin/ NA and isoprenaline stimulation of [ H]cAMP 
formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
forskolin (•)/ NA ( O)  and isoprenaline ( A)  for 10 min in the 
-5
presence of 10 M RO 20-1724. Results are means _+ S.E.M. of 3 
experiments.
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-5
propranolol inhibited NA (10 M) stimulation of cAMP formation by
30%, 35% and 60% respectively. This suggests that although prazosin
was the most potent adrenergic antagonist propanolol was more effective
-5
than yohimbine or prazosin at inhibiting the NA (10 M) stimulation 
of cAMP formation (Fig. 34). The results suggest that NA stimulation of
cAMP formation was due to the synergistic effect of a , a and ft
1 2 K
-adrenoceptors.
Propranolol at submicromolar concentrations (10 "^M -
-7 -6
10 M) blocked isoprenaline (10 M) stimulation of cAMP formation,
-6 -5
and complete inhibition was observed at 10 M and 10 M propranolol 
(Fig. 35). This shows that isoprenaline is a ^-adrenergic agonist 
since its stimulation of cAMP formation is blocked completely by the 
J3-adrenergic antagonist, propanolol.
3.3.1.2 Stimulation of cAMP formation by adenosine in the absence or 
presence of IBMX and RO 20-1724
Adenosine stimulated cAMP formation in chopped'brain slices in
a concentration-dependent manner (Fig. 36) with an EC value of
50
-5
6 x 10 M. A maximum stimulation of 2.7 - 3.5 fold was achieved by
-3 -4
adenosine (10 M). In the presence of IBMX (10 M), the dose
response of adenosine was shifted to the right, suggesting that IBMX
inhibits cAMP formation by acting at adenosine A^ receptors (Fig. 36).
-5
In contrast, RO 20-1724 (10 M) elevated the basal level of cAMP
-5
formation, but it did not affect the EC_rt value (6 x 10 M) of
5U
adenosine stimulation of cAMP formation (Fig. 36).
3.3.1.3 Effects of (X - and ft-adrenergic antagonists on adenosine
combined with NA stimulation of cAMP formation
-7
Low concentrations of adenosine (10 M) did not affect the 
-5
basal as well as NA (10 M) stimulation of cAMP formation (Fig. 37).
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Figure 34 Effect of prazosin, yohimbine and propranolol on NA 
stimulation of cAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with 
different concentrations of prazosin (A), yohimbine (O)
-5
propranolol (H ) in the presence of 10 M NA for 10 min. The
basal level of cAMP formation was 0.64 +_ 0.04% conversion, and
-5 .
10 M NA stimulated cAMP formation by 1.5 0.08% conversion.
-5
Therefore 10 M NA stimulation increased cAMP level by 0.87% 
conversion, and this was expressed as 100% control on the figure. 
Results are means _+ S.E.M. of 4-6 experiments.
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Figure 35 Effect of propranolol on isoprenaline stimulation of cAMP 
formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
-6
different concentrations of propranolol in the presence of 10 M 
isoprenaline for 10 min. Basal level of cAMP formation was 0.56 _+ 0.02% 
conversion, and isoprenaline stimulation of cAMP formation was 
0.98 +_ 0.03% conversion. Therefore, isoprenaline stimulation increased 
cAMP formation by 0.42% conversion, and this is expressed as 100% of 
control on the figure. Result is the representative of 2 experiments.
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Figure 36 Influence of IBMX and RO 20-1724 on adenosine stimulation
of cAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
different concentrations of adenosine (O) either in the presence of
-4 -5
10 M IBMX (A  ) or 10 M RO 20-1724 (Q) for 10 min. Results are
means _+ S.E.M. of 3 experiments.
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However, adenosine at 10 M potentiated NA (10 M) stimulation of 
cAMP formation by 0.7 fold, taking into account the individual NA and 
adenosine stimulation of cAMP formation (Fig. 37),. a^-Adrenergic 
antagonist, yohimbine, a^-adrenergic antagonist, prazosin and
(3-adrenergic antagonist, propranolol blocked the adenosine
-4 -5
(10 M)combined with NA (10 M) stimulation of cAMP formation in a
concentration dependent manner (Fig. 38) with IC values of 8 x
50
-9 -9 -7
10 M, 2.5 x 10 M and 6 x 10 M for yohimbine, prazosin and
propranolol respectively. This suggests a potency order of
-5
yohimbines prazosin S  propranolol (Fig. 38 ). At 10 M
concentration yohimbine, prazosin and propranolol inhibited adenosine
-4 -5
(10 M) combined with NA (10 M) stimulation of cAMP formation by
40%, 30% and 22% respectively. This suggests that yohimbine is a more
potent and effective adrenergic antagonist at inhibiting adenosine
-4 -5
(10 M) combined with NA (10 M) stimulation of cAMP formation than
prazosin and propranolol. In contrast, propranolol was shown to be 
the most effective adrenergic antagonist at inhibiting NA stimulation 
Of cAMP formation (Fig. 34 ). In other words the adenosine component 
is more sensitive to a-adrenergic than -adrenergic antagonists.
3.3.1.4 Influence of forskolin on NA, isoprenaline and adenosine
stimulation of cAMP formation 
-7
Forskolin (10 M) which did not affect the basal level of
-5 -6
cAMP formation potentiated NA (10 M), isoprenaline (10 M) and
-4
adenosine (10 M) stimulation of cAMP formation (Fig. 39) by 0.7, 0.8
-6
and 1.5-fold respectively. However, forskolin (10 M and 5 x 
-6
10 M) which itself stimulated cAMP formation was only able to 
increase NA, isoprenaline and adenosine stimulation of cAMP formation 
in an additive manner (Fig. 39).
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Figure 37 Effect of adenosine on NA stimulation of cAMP formation 
in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
-7 -4 -5
adenosine (10 M; 10 M) or NA (10 M) or both for 10 min.
Results are means S.E.M. of 4 experiments.
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Figure 38 Effect of (X - and ft-adrenergic antagonists on., adenosine
and NA stimulation of cAMP formation
3
Tissue chops labelled with [ H] adenine were preincubated with
different concentrations of propanolol (8H), prazosin (A) and
-4
yohimbine (O ) for 10 min in the presence of adenosine (10 M)
-5
combined with NA (10 M) for 10 min. The basal level of cAMP
formation was 0.55% conversion, while adenosine combined with NA
stimulated cAMP formation to 3.55% conversion. Therefore, adenosine 
combined with NA increased cAMP formation by 3.0% conversion, which is 
expressed as 100% control on the figures. Results are means _+ S.E.M. 
of 5 experiments.
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Figure 39 Effect of forskolin on NA, isoprenaline and adenosine 
stimulation of cAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then  incubated with lOpM 
NA, lpM isoprenaline (Iso) or lOOpM adenosine (Ads) either in the 
absence (§j|) or presence of O.lpM o ), lpM (||) or 5pM (|H}) forskolin 
for 10 min. Results are means _+ S.E.M. of 3 experiments.
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3.3.2 K_+ stimulation of.cAMP formation in the absence or presence
of IBMX, RO 20-1724 or DMI
l^tassium-stimulated cAMP formation in O.C. tissue chops
(Fig. 40). Maximuinirrc^eased in cAMP formation of 2.2 fold was
+ _
achieved by 40mM K and remained effectiv^eiy^onstant until 80mM.
+
Increasing K above 80mM led to a decrease in cAMP formatlbrr^-^JThere
+
is no evidence that IBMX or RO 20-1724 enhanced K stimulation of 
cAMP formation when compared to their respective control (Fig. 41).
DMI was included in the release experiments to prevent 
3
re-uptake of release of [ H]NA (Fig. 13), thus it was important to
see if it had any effect on cAMP formation. However, no evidence was 
-6
found that DMI (10 M) modified cAMP formation under depolarizing 
condition (Fig. 42).
+
3.3.2.1 Influence of forskolin on K stimulation of cAMP formation
-4 +
Forskolin (10 M) in the presence of 5mM and 20mM K
stimulated cAMP formation by about 9 fold. However, in the presence
+ - 4
of 40mM and 60mM K , cAMP formation due to forskolin (10 M) was
reduced by 50% and 100% respectively (Fig. 43). RO 20-1724 increased
+ + 
the basal level (5mM K ) as well as 40mM K stimulation of cAMP
formation in a concentration-dependent manner (Fig. 44). in the
-3 -5
presence of RO 20-1724 (10 M), forskolin (10 M) stimulation of
+
cAMP formation was not reduced to half with 40mM K depolarization
(Fig. 44). This suggests that the decrease in cAMP formation observed
+ +
with forskolin in the presence of 40mM K and 60mM K may due to
2+
the stimulation of Ca -dependent PDE, activated by the influx of
2+ +
Ca into tissue chops following K depolarization.
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Figure 40 K stimulation of cAMP forination in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine for half an hour and
+
then incubated with different K concentrations for 10 min. Results 
are means + of 4 experiments.
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Figure 41 Effect of IBMX and RO 20-1724 on K* stimulation of cAMP
formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
+ . 
different K concentrations either alone ({_J) or in the presence of
-4 __ -5
10 M IBMX ({^) or 10 M RO 20-1724 (|§§) for 10 min. Results are
means _+ S.E.M. of 4 experiments.
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Figure 42 Effect of DMI on K -stimulation of cAMP formation in 
O.C. tissue chops
Tissue chops were labelled with [ H] adenine then incubated with
different K+ concentrations either in the presence ( □  ) or absence (j|§) 
-6
or 10 M DMI for 10 min. Results are means +_ S.E.M. of 3 experiments.
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Figure 43 Influence of forskolin on K+ stimulation of cAMP
formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
+ _ _
different K concentration either alone (§|j) or in the presence of
4 __
10“  M forskolin ((__j) for 10 min. Results are means S.E.M. of
3 experiments.
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Figure 44 Effect of RO 20-1724 and forskolin on K stimulation of 
cAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then incubated with
RO 20-1724 and forskolin in either 5mM or 40mM K+ for 10 min.
Results are means + S.E.M. of 3 experiments.
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3.3.3 Effect of (X^ -adrenergic agonists in the presence of various 
cAMP stimulating agents:
3.3.3.1 Forskolin
-5
Forskolin (10 M) stimulated cAMP formation 3-5 fold. 
Increasing concentrations of the a^-adrenergic agonist, UK 14304-18, 
had no effect on forskolin stimulation of cAMP formation (Fig. 45).
This is further supported by the observation that neither UK 14304-18
-5 -6
(10 M; Fig. 46) nor clonidine (10 M; Fig. 47) affected the
forskolin dose response curve.
3.3.3.2 Noradrenaline (NA)
a^-Adrenergic agonists, BHT-920, clonidine and UK 14304-18 
-5
inhibited NA (10 M) stimulation of cAMP formation in a biphasic and
concentration dependent manner (Fig. 48) with IC values of
50
-7 -8 -9
5 x 10 M, 10 M and 6 x 10 M respectively. This suggests a
potency order of UK 14304-18 >  clonidine >  BHT-920. At concentration 
-5
of 10 M, BHT-920, clonidine and UK 14304-18 maximally inhibited the 
-5
NA (10 M) stimulation of cAMP formation by 22%, 30% and 55%
respectively (Fig. 48). The results indicate that UK 14304-18 is the
most potent and effective (X^-adrenergic agonist. This is further
-5
supported by the evidence that UK 14304-18 (10 M) shifted the dose
response curve of NA to the right (Fig. 49). On the contrary, the
-5
OC^-adrenergic agonist, phenylephrine (10 M) did not affect the
dose response curve of NA (Fig. 49). This suggests that only the
OC ^ -adrenergic agonist inhibits NA stimulation of cAMP formation.
-5
UK 14304-18 (10 M) did not affect the dose-response curve of
-5
isoprenaline (Fig. 50). On the contrary, phenylephrine (10 M)
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Figure 45 Dose response of UK 14304-18 on forskolin stimulation of 
cAMP formation in O.C. tissue chops
Tissue chops were labelled with [ H] adenine then preincubated with
different concentrations of UK 14304-18 for 5 min and then further
-5
incubated in the presence of 10 M forskolin for 10 min. Basal
-5
level of cAMP formation was 0.85 _+ 0.06% conversion, and 10 M
forskolin stimulated cAMP formation 4.8 _+ 0.08% conversion.
-5
Therefore, 10 M forskolin stimulation increased cAMP formation by 
3.95% conversion, which is expressed as 100% on the figure. Result is 
the mean + S.E.M. of 3 experiments.
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Figure 46 Effect of UK 14303-18 on forskolin dose response
stimulation of cAMP formation in O.C. tissue chops
3
Tissue chops were labelled with [ H] adenine then preincubated in the
-5
absence (• ) or presence (O  ) of 10 M UK 14304-18 for 5 min and then 
further incubated in the presence of different concentrations of 
forskolin for 10 min. Results are means _+ S.E.M. of 4 experiments.
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Figure 47 Effect of clonidine on forskolin dose response
stimulation of cAMP formation in O.C. tissue chops
Tissue chops were labelled with [ H] adenine then preincubated in the
-5
presence (O  ) or absence (O ) of 10 M clonidine for 5 min and then 
further incubated in the presence of different concentrations of 
forskolin for 10 min. Results are means +_ S.E.M. of 3 experiments.
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Figure 48 Effects of BHT-920, clonidine and UK 14304-18 on NA 
stimulation of cAMP formation in O.C, tissue chops
3
Tissue chops were labelled with [ H] adenine then preincubated with 
different concentrations of BHT-920 (B), clonidine ( O )  and
UK 14304-18 (•) for 5 min, and then further incubated for 10 min in 
-5
the presence of 10 M NA. The basal level of cAMP formation was
-4
0.53% conversion, while 10 M NA stimulated cAMP formation to 1.5% 
conversion. Therefore, NA stimulation increased cAMP formation by 
0.97% conversion, which is expressed as 100% control on the figure. 
Results are means S.E.M. of 6 experiments.
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Figure 49 Effect of phenylephrine or UK 14304-18 on NA stimulation 
of cAMP formation in O.C, tissue chops
3
Tissue chops were labelled with I H] adenine then preincubated with
-5 -5
10 M phenylephrine (A) or 10 M UK 14304-18 (□) for 5 min and
then further incubated with increasing concentrations of NA in the 
presence of respective drugs mentioned above or alone (®) for 
10 min. Results are means _+ S.E.M. of 4 experiments.
[Isoprenaline] M
Figure 50 Effect of phenylephrine or UK 14304-18 on isoprenaline 
stimulation of cAMP formation in O.C, tissue chops
3
Tissue chops labelled with [ H] adenine were preincubated with
-5 -5
10 M phenylephrine ( A )  or 10 M UK 14304-18 (□) for 5 min and
then further incubated with increasing concentration of isoprenaline in
the presence of respective drugs mentioned above or alone (•) for
10 min. Results are means ±  S.E.M. of 3 experiments.
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potentiated the dose-response curve of isoprenaline (Fig. 50). The 
results show that the a^-adrenergic agonist was able to potentiate 
the J3~adrenergic agonist stimulation of cAMP formation.
3.3.3.3 Adenosine
-5
UK 14304-18 (10 M) slightly potentiated the stimulation of 
-5
cAMP formation by 10 M adenosine (Fig. 51). However, a greater
potentiation (0.9-fold) was observed at higher concentrations of 
-3
adenosine (10 M). The ECcr. value for adenosine stimulation ofou
-5
cAMP formation was not altered by UK 14304-18 (10 M).
+
3.3.3.4 K
—  6 +
UK 14304-18 (10 M) did not affect K stimulation of cAMP
-5
formation in the absence or presence of RO 20-1724 (10 M) (Fig. 52)
-5
The apparent slight inhibition observed with 10 M UK 14304-18 and 
+
20mM K was statistically insignificant.
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Figure 51 Effect of UK 14304-18 on adenosine stimulation of cAMP 
formation in O.C. tissue chops
3
Tissue chops labelled with [ H] adenine were preincubated in
-5
the absence ("O ) or presence (□) of 10 M UK 14304-18 for 5 min, and 
then further incubated with different concentrations of adenosine for 
10 min. Results are means _+ S.E.M. of 4 experiments.
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Figure 52 Effect of UK 14304 on K+ (in the absence or presence of 
RO 20-1724) stimulation of cAMP formation in O.C. tissue 
chops
3
Tissue chops labelled with [ H] adenine were preincubated in the
absence or presence of UK 14304-18 indicated on the figure for 5 min,
and then further incubated with different [K ] in the absence (f8|)
+
or presence (|gg)of UK 14304-18, or with different [K ] combined with 
RO 20-1724 in the absence (Q) or presence ({§§) of UK 14304-18 for
10 min. Results are means _+ S.E.M. of 3 experiments.
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4. DISCUSSION
A large number of studies have provided evidence that receptors 
located on nerve endings regulate the release of neurotransmitters. The 
presynaptic regulation of neurotransmitter release was initially studied 
in the peripheral nervous system (Langer, 1977, 1981) but has since been 
shown to occur in the central nervous system (CNS)(Taube et al., 1977; 
Chesselet, 1984; Middlemiss, 1988). For example, an CX^-adrenergic 
agonist such as clonidine, has been shown to regulate the release of NA 
(Reichenbacher et al., 1982; Schoffelmeer and Mulder, 1983) and 
serotonin (Frankhuyzen and Mulder, 1982; Ellison and Campbell, 1986) 
from the CNS. However, although a considerable amount of work has been 
carried out on the presynaptic regulation of neurotransmitter release, 
little information is available about the second messenger mediating 
this regulation. Thus, the aim of this project was to examine the 
hypothesis that the CC^-adrenergic regulation of NA release from O.C. 
and hypothalamic tissue chops was associated with a decrease in cAMP 
formation. The results presented in this thesis will be discussed 
under three main headings -
(1) The use of tissue chops and incubation assay to study the 
release of NA,
(2) a^-Adrenergic regulation of NA release, and
(3) The possible role of cAMP in mediating the a^-adrenergic 
regulation of NA release.
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4.1 The use of rat brain tissue chops and incubation assay to study
NA release
4.1.1 Choice of brain region
In this study, the NA concentration found in the hypothalamus 
was 1404 +_ 251ng/g. This is in agreement with literature values of 
1370 Hh 50ng/g (Holtzman, 1974) and 1622 +_ 182ng/g (Oke et al., 1978).
The DA concentration of the hypothalamus in this study was found to be 
220 +_ 16 ng/g. This is in agreement with the findings of Shellenberger, 
(1971) who reported a value of 260 _+ 20ng/g. The NA and DA 
concentrations found in the O.C. were 502 +_ 347ng/g and 59 +_ 18ng/g 
respectively, which agree well with the values of 380 +_ 40ng/g and 
65.9 +_ 0.2ng/g reported by Westerink and Mulder (1981). Thus, the NA 
content of the brain regions chosen for the present study agreed with 
the literature values. This provides confirmation that the correct 
brain regions were identified and that they contain noradrenergic nerve 
endings.
4.1.2 Comparison between tissue chops and synaptosomes preparations
The two preparations frequently used for the in vitro study of
biochemistry in the CNS are: (i) chopped brain slices and (ii)
synaptosomes. The advantage of using chopped brain slices is that they 
are a more intact preparation in which to study biochemical mechanism 
associated with neuronal function, without the influence of blood brain 
barrier. In particular, most studies on presynaptic regulation of 
nerve terminals have used a more intact system that is provided by 
synaptosomes (Middlemiss, 1988). One problem to consider when working 
with brain slices is that thick slices may become anoxic (Palfrey and 
Mobley, 1987), which will disrupt the energy metabolism of the neurons.
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In addition, anoxia increases cAMP levels (Gross and Ferrendelli, 1980), 
thereby affecting neurotransmitter release. On the other hand, thin 
slices may not contain enough nerve endings making typical synaptic 
contacts (Palfrey and Mobley, 1987). The thickness of brain slices 
routinely used to study presynaptic regulation of neurotransmitter 
release and cAMP formation range between 0.2mm to 0.3mm (Carmichael and 
Israel, 1973; Gothert, 1979; Schoffelmeer et al., 1986) and 0.26mm 
respectively (Perkin and Moore, 1973; Karbon and Enna, 1985). Because 
of this, tissue chops of 0.26mm in thickness were used in the present 
study.
Synaptosomes are pinched off nerve terminals containing 
mitchondria and small vesicles filled with neurotransmitters (Gray and 
Whittaker, 1962; Gordon-Weeks, 1987). Thus, they have the capacity to 
synthesize, store, release and metabolise neurotransmitters (Deutsch 
et al., 1981). One advantage of synaptosomes is that they are less 
heterogenous than tissue chops. Most preparations of synaptosomes, 
however, still contained significant numbers of other particles such as 
fragmented membranes, myelin sheath and free mitochondria (Gordon-Weeks,
1987). Besides this, they usually contain a heterogenous population of 
nerve endings, and so do not, in this sense, represent a purer 
preparation than tissue chops. Furthermore, synaptosomes possess high 
osmotic sensitivity (Marchbanks, 1967; Keen and White, 1971) thereby 
giving rise to "spurious release" of endogenous neurotransmitter. In 
addition, some researchers (Lane and Aprison, 1977; Mulder et al.,
1978; De Langen et al., 1979) find that it is difficult to demonstrate 
consistent regulation of neurotransmitter release by presynaptic 
receptors with synaptosomes preparations. Thus, they concluded that 
synaptosomes are not ideal preparations for a study on presynaptic
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regulation of neurotransmitter release. In view of this, chopped brain 
slices were selected for the study of o^-adrenergic regulation of NA 
release in the occipital cortex (O.C.) and hypothalamus of rat brain.
4.1.3 Comparison between superfusion and incubation assays
Neurotransmitter release from brain slices or synaptosomes is
usually studied by preloading the preparations with radioactive
neurotransmitter. Depolarization-stimulated release is then followed
3
by measuring the efflux of labelled triated [ H] neurotransmitter into 
the superfusion or incubation fluids. Advantages and disadvantages of 
both the assays are discussed below.
(a) Superfusion assay; In this assay, preloaded brain slices or
synaptosomes are placed on a filter, and the superfusion fluids are
pumped over them at a regular flow rate, the superfusates are collected
in separate tubes. The release, expressed as a percentage of total
tissue tritium, is usually calculated as the ratio of a second
stimulation, S to the first stimulation, S .
2 1
The advantage of superfusion technique is that the brain slices 
or synaptosomes are continuously exposed to fresh superfusion fluids, 
reducing the problem of re-uptake and feedback regulation effects. One 
disadvantage of superfusion is that clogging of filter may occur, which 
may then affect the maintenance of regular flow rates. Furthermore, 
relatively large volumes of buffer are needed, which can lead to large 
use of expensive chemicals.
(b) Centrifugation assay: In this assay, preloaded brain slices are
distributed in a small volume into different Eppendorf tubes. Here, 
only a small volume (i.e. 0.5ml) is required. Stimulus evoked release 
of neurotransmitters is studied by incubating the brain slices in the
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* +
Eppendorf tubes containing high K with regular shaking for a short
period of time. Release is terminated"; by rapidly centrifuging the
Eppendorf tubes. The supernatants are removed and collected in
different vials. The remaining tritium in the pellet is extracted with
PCA. The release of tritiated noradrenergic neurotransmitter 
3
([ H]NA) expressed as a percentage of total tissue tritium is 
calculated as below:
_ ,3. , cpm(supernatant)% release of [JH jNA =  —  ---- -— —  ----------------------
cpm (pellet) + cmp (supernatant) x 100
The advantage of using centrifugation assay is that small
amounts of buffer are required, with a more economical use of agonists
and antagonists. In addition, more concentrated solutions of released
neurotransmitters can be achieved. Another advantage of using
centrifugation assay is that it provided a convenient technique in which
to compare the effect of a^-adrenergic agonists on both NA release
and cAMP formation under comparable conditions. However, the main
disadvantages of this assay are that the re-uptake and feedback
inhibition (autoinhibition) of the release of NA at the nerve terminals
may be more pronounced than in the superfusion system. An important
3
stage in the present study therefore, was to establish that [ H]NA 
release from rat brain tissue chops using incubation assay gave results 
consistent with those reported in the literature for the superfusion 
technique. The use of incubation assay has also been reported in the 
study of endogenous NA and DA release from rat brain slices (Lane and 
Aprison, 1977; Kant and Meyerhoff, 1978 ) as well as the 
neurotransmitter release from cells in monolayer (Marriott et al., 1988).
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4.1.4 Influence of uptake inhibitors on the regulation of NA release 
The tricyclic antidepressant imipramine and its metabolites
desipramine (DMI), 2-hydroxyimipramine and 2-hydroxydesipramine (Javid
et al., 1978) as well as narcotic analgesics including codeine, cocaine,
morphine, naloxone and methadone (Carmichael and Israel, 1973) have been
-6
shown to inhibit the uptake of NA. In the present study, DMI (10 M)
3
inhibited the uptake of [ H]NA by 90% (Fig. 13). In the absence of
3
DMI, the basal release of [ H]NA has beeen shown to consist of only
3 3
10% [ H]NA while the remaining 90% was [ H] metabolites of NA (Taube
et al., 1977). In the presence of DMI, however not only is the basal 
3
release of [ H] metabolites is strongly reduced (Taube et al., 1977),
but also in the presence of uptake inhibitors including cocaine and DMI,
+ 3
electrical as well as K -stimulated release of [ H]NA consisted
3
mainly of [ H]NA and not its metabolites (Langer et al., 1976; Taube
et al., 1977). Two possibilities are that uptake inhibitors are either
acting as monoamine oxidase inhibitors, or else they are increasing the
uptake into storage vesicles which thus protects NA from metabolism.
-6
Thus, in the present study, DMI (10 M) was added in the incubation 
medium of centrifugation assay in the study of NA release experiments.
+ 2+ 3
4.1.5 K stimulated Ca dependent release of [ H]NA
3
Release of [ H]NA from brain slices or synaptosomes is usually
stimulated electrically or by exposing the tissue preparation to high 
+
K concentration (Schoffelmeer, 1981; Daniel and Leslie, 1986). It
is generally accepted that depolarization whether achieved electrically 
+
or by increasing K concentration activates the voltage sensitive 
2+
Ca channels and that neurotransmitter release is induced by the
2+
consequent rise in intracellular Ca . Other depolarizing agents
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including veratrine and scorpion venom have also been shown to increase
*u 45 2+the ca uptake in rat brain synaptosomes (Blaustein, 1975).
+
The present result demonstrates that 20mM or 40mM K 
3
stimulation of [ H]NA release from O.C. tissue chops is dependent on
2+ 3
Ca (Fig. 16) while basal (5mM) release of [ H]NA is not affected
2+
by Ca throughout the range 0.5mM - 2.0mM (Fig. 16). Similarly, 
non-depolarized induced release of endogenous NA using synaptosomes
prepared from rat hypothalamus, brainstem and cerebellum brain regions
2+ ,
is not dependent on Ca (Daniel and Leslie, 1986). The release of 
3
[ H]NA has been shown to be directly proportional to the membrane
+
potential developed by different K concentration throughout the range
+ +
13 - 120mM K (Dismukes et al., 1977). This suggests that K
provides a suitable stimulus for studying release from rat brain tissue
+ 2+ 
chops. K -stimulated Ca -dependent release is also observed in
other neurotransmitter systems including GABA (Cotman et al., 1976),
serotonin (Klein and Kendal, 1980) acetylcholine (Suszkiw and O'Leary,
1983; Tanaka et al., 1985) and dopamine (Leslie et al., 1985).
+
Schoffelmeer et al. (1981) found that 20mM K -stimulated
3 2+
release of [ H]NA reached a maximum value between 0.6mM - 0.9mM Ca
2+
followed by a slight decrease at 2mM Ca . They also found that high
2+ ' 45 2+
Ca concentrations (2-5mM) decreased Ca release from rat
3 2+
brain slices. The decrease in [ HJNA release at high Ca
2+
concentrations suggest that Ca inhibits its own transport through 
2+
Ca channels in the nerve terminals. In contrast, no inhibition of
+ + 3
20mM K or 40mM K -stimulated release of [ H]NA is observed at 2mM
2+
Ca in the present study (Fig. 16). This is in agreement with
Cotman et al. (1979) who found no inhibition of K+ stimulated release
2+
of Y  -aminobutynic acid (GABA) and NA using superfusion method by Ca 
concentrations above 2mM.
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Orrego (1979) reported that Ca independent release of
neurotransmitter originating from extravesicular cytoplasmic pools was
increased under strongly depolarizing conditions. Therefore, mildly 
+
depolarizing K concentration (20mM) was used in the present study to
decrease the contribution of NA release from non-vesicular pools.
The brain consists of several cell types in addition to
neurons. Electrophysiological studies show that one of these cell
+
types, glia, express K channels (Bevan and Raff, 1985). Furthermore 
primary cultures of glial cells have been shown to accumulate 
neurotransmitters (Kimelberg and Katz, 1986). Thus, the contribution 
of glia to the release of neurotransmitter should be considered.
Sugino et al. (1984) found that stimulation of cultured rat astrocytoma
+ 2+ 
cells, C6 BU-1 with 50mM K did not increase the intracellular Ca
concentrations. Also, when neurotransmitters such as NA, DA and
acetylcholine are applied to glia cell cultures in the presence of the 
2+
Ca indicator, Quin 2, no change m  fluorescence is observed,
2+
indicating that there is no change in intracellular Ca (Sugino
et a1., 1984). This implies that glial cells do not express
2+ + 
voltage-dependent Ca channels. Thus, K -stimulated release of
3
[ H]NA from chopped brain slices in the study is mainly of neuronal 
origin.
3
4.1.6 Conditions for a^-adrenergic regulation of [ H]NA release 
Noradrenaline regulates its own release via a^-adrenergic 
receptors located on noradrenergic nerve endings (Starke, 1979; Langer, 
1981). These receptors are described as the 'presynatic autoreceptors', 
the first term referring to their location on nerve terminals and the 
second to their sensitivity to the neurotransmitter released by the 
neurons themselves (Chesselet, 1984).
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The present study shows that the a^-adrenergic agonist,
+ 3
clonidine, inhibition of 30mM K -stimulated release of [ H]NA from
O.C. tissue chops does not depend on pretreatment of tissue chops (Figs.
+
17, 18). Thus clonidine inhibition of 30mM K stimulation of 
3
[ H]NA release is the same whether clonidine is preincubated for up to
30 min (Fig. 18) or added immediately (Fig. 18) before evoking release 
+
with K . This suggests that the effect of clonidine is very rapid.
On the contrary, in superfusion studies, tissues are normally superfused 
with drugs for 20 - 30 min. (Werner et al., 1981; Ueda et al., 1983) as 
it is generally presumed to obtain a better effect of the drugs on the 
regulation of neurotransmitter release.
Clonidine inhibition of NA release is dependent on the extent of
+ +
K depolarization, since clonidine inhibited 40mM, 30mM and 20mM K
3
stimulation of [ H]NA release by 17.0%, 37% and 50% respectively (Fig.
19). The results obtained in the present study is in agreement with
the findings of Werner et al. (1981) using another a2~a<3rener9ic
agonist, oxymetazoline who report that at low depolarizing stimuli a
greater proportion of NA release is subject to a^-adrenergic agonist
inhibition. One possible explanation is that a^-adrenergic agonists 
+
may increase K permeability during depolarization, thereby leading to
+
hyperpolarization which is more pronounced at low K concentrations.
This could then lead to a decrease in NA release as shown in the 
peripheral nervous system (Alberts et al., 1981; Zimanyi et al. ,
1988). Another alternative explanation provided is that
2+CL ^-adrenergic agonists inhibit the voltage-sensitive Ca channels
(Gothert et al., 1979; Langer, 1981), and that this effect is more
2+
clearly observed at suboptimum depolarization conditions when Ca 
influx might be expected to be rate limiting. In contrast,
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Schoffelmeer and Mulder (1984) demonstrated that Cc ^ -adrenergic
3
agonists, NA and clonidine inhibition of [ H]NA release from rat brain
cortex slices is independent of the degree of depolarization when the
+
release was effected by 15mM or 56mM K . Instead the activation of
2+
these presynaptic receptors causes a decrease in Ca availability or
2+
the utilization of Ca by the secretion process upon invasion of an 
action potential.
+
4.1.7 Influence of oxygenation on the effect of K and clonidine on 
3
[ H]NA release
+
The present study demonstrates that K -stimulated as well as 
3
basal release of [ H]NA from rat O.C. tissue chops is higher in non
oxygenated (Figs. 14, 19) than in oxygenated HEPES buffer (Figs. 14, 19).
Furthermore, clonidine is less effective at inhibiting NA release in
non-oxygenated than in oxygenated HEPES buffer (Fig. 19). One possible
explanation would be that anoxia increases cAMP formation (Gross and
+
Ferrendelli, 1980), thus leading to the enhanced K -stimulated release 
3
of [ H]NA, thereby overcoming the a 2~adrenergic inhibition of 
+
K -stimulated release. Alternatively, since anoxia also effects 
glucose metabolism of the cell,thus altering the phosphorylation state 
of regulatory proteins and this could affect the release of 
neurotransmitters (Gross and Ferrendelli, 1980). Thus, all release 
experiments were carried out with the HEPES buffer equilibrated with 95% 
0 ■- 5% CO^ and then adjusting the pH to 7.4 before use. Using 
this procedure, the degree of inhibition observed with clonidine is 
comparable with that obtained by the superfusion technique (Taube 
et al., 1977; Werner et al., 1979).
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3
4.2 g ^-Adrenergic regulation of [ H]NA release from rat O.C.
and hypothalamic tissue chops
Autoradiographic study shows that both and
a^-adrenoceptors are widely distributed in the intact rat brain
tissue (Young and Kuhar, 1979; 1980). Based on a pharmacological
characterization study CX-adrenoceptors in rat brain cortex are found to
be exclusively of Q^-type (Hedler et al., 1981). However, a
6-hydroxydopamine-induced destruction of noradrenergic nerve terminals
increases rather than decreases the number of receptor binding sites of
C^-ligand, clonidine (U * Prichard and Snyder, 1979), thus suggesting a
pre- and post-synaptic location of a^-adrenoceptors.
The present study compared the effect of the a^-adrenergic
+
agonists, clonidine, BHT-920 and UK 14304-18 with NA on the K 
3
stimulation of [ H]NA release from O.C. tissue chops. It was found
■ +
that a 2~adrenergic agonists inhibit 20mM K -stimulated release of 
3
[ H ]NA with the following order of potency (IC,.n values in
ou
-7 -7
parenthesis), UK 14304-18 (1 x 10 M) >  clonidine (3.5 x 10 M) ‘P7’
-7 -7
BHT-920 (5.5 x 10 M) x7, NA (8.5 x 10 M) and a maximum inhibition of
-5
70%, 53%, 37% and 84% respectively achieved at 10 M concentration of
these agonists (Fig. 20). This shows that although UK 14304-18 is the
most potent ^-adrenergic agonist, it is not as effective as NA.
UK 14304-18 has also been shown to be more potent than clonidine and NA 
3
at regulating [ H]NA release from ileum and pulmonary artery
(Cambridge, 1981; Van Meel et al., 1981). Ligand-binding studies in
rat brain membranes showed that UK 14304-18 is highly selective for
-9
a 2-adrenoceptors as UK 14304-18 (10 M) displaced bound
3
OC^-adrenergic agonist, [ H] clonidine by 50% whereas a
-6
concentration of 10 M was needed to displace the Ct^-adrenergic 
3
antagonist, [ H] prazosin by an equivalent amount (Cambridge, 1981).
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This confirms that ’UK 14304-18 is both a selective and potent
a.2-adrener9ic agonist. Since clonidine (Medgett et al., 1978) and
BHT-920 (Lues and Schumann, 1984) have been shown to be partial
adrenergic agonist in the smooth muscle, it then suggests that the lower
effectiveness of both clonidine and BHT-920 may possibly be due to the
pre- and post-synaptic effect of both drugs. In contrast, Chicini and
Singer,(1987) showed that BHT-920 acts mainly as presynaptic
a^-adrenergic agonist on the electrical stimulated release of 
3
[ H]NA from rat brain cortex and hypothalamus.
The hypothalamic tissue chops, NA and clonidine at submicromolar
-7 -6 +
concentrations (10 M - 10 M) inhibited 30mM K -stimulated
3
release of [ H]NA to the same extent (Fig. 21). At higher
-4
concentrations, however, NA (10 M) is shown to be more effective than
— 4 +
clonidine (10 M) at inhibiting the 30mM K -stimulated release of
3
[ H ]NA (Fig. 21). This finding is in agreement with more effective
+ 3
inhibition of 20mM K -stimulated release of [ H]NA from the O.C.
tissue chops by NA than clonidine. Using superfusion techniques, other
researchers have also shown that a^-adrenergic agonists including NA,
+
clonidine, phenoxybenzamine and oxymetazoline inhibited K and
3
electrical stimulation of [ H]NA release in rat brain slices (Taube
et al., 1977; Werner et al., 1982; Reichenbacher et al., 1982;
Chesselet, 1984; Middlemiss, 1988) and synaptosomes (Lane and Aprison,
1977; De Langen et al., 1979). The results presented in this thesis
show that the method used to examine a^-adrenergic agonists 
3
inhibition of [ H]NA release gives comparable results to those 
reported in the literature. The ce^-adrenergic antagonist,
yohimbine, not only reversed the inhibition caused by a  -adrenergic
+
agonists but also (Figs. 22, 25) enhanced the K -stimulated release of
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3
[ H]NA from O.C. and hypothalamic tissue chops by 25% and 10% at 
-6 -5
10 M and 10 concentrations respectively (Figs. 20, 21). This
+
suggests that endogenous NA is able to inhibit the K -stimulated 
3
release of [ H]NA from O.C. and hypothalamic tissue chops by acting 
at (X^-adrenoceptors. Similarly, using superfusion technique Werner
et al. (1979) found that OC -adrenergic antagonists, yohimbine and
+ 3
phentolamine enhanced the K -stimulated release of [ H]NA by 60% and
-5
90% at 10 M concentration respectively from rat frontal cortex brain 
slices. Thus they concluded that presynaptic Ot-adrenoceptors are
partially activated by released endogenous NA thereby reducing the
+ 3
K -evoked release of [ H]NA. This view is supported by the
3
observation that phentolamine does not enhance the release of [ H]NA
from synaptosomes since with this preparation endogenous NA is more
effectively removed by superfusion medium than from brain slices (De
Langen et al., 1979). It is interesting that less inhibition of
release appears to take place with the assay used in this study than in
the perfusion system used by Werner et al. (1979). Thus endogenous NA
appears to have less effect on release in this study than in the work
reported by Werner et al. (1979).
In contrast to the effect of a^-a^renergic antagonist
yohimbine, in O.C. tissue chops, the a^-adrenergic antagonist,
prazosin (Fig. 24) and p-adrenergic antagonist, propranolol (Fig. 23)
+
did not reverse the NA inhibitory effect of K -stimulated release of 
3
[ H ]NA. The present results are, in agreement with the findings of
Taube et al. (1977) and Reichenbacher et al. (1982) who also show that
propranolol and prazosin had no effect on the stimulated release of 
3
[ H]NA from both rat and rabbit cortical slices. This suggests that 
in O.C. tissue chops, only the CX^-adrenoceptors are involved in the
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+ 3
regulation of K -stimulated release of [ H]NA. Furthermore, in
O.C. tissue chops, propranolol increased the inhibitory effect of NA
-6 -5
when the concentration of NA increased from 10 M to 10 M
(Fig. 23). Similarly, in the peripheral nervous system, NA inhibition
+ 3
of K -stimulated release of [ H]NA increased when the concentration
of propranolol was increased (see Langer, 1981 for review). One
possible explanation is that propranolol which block the
p-adrenoceptors increases the effective concentrations of NA in the
vicinity of the nerve terminals, thereby allowing more NA to activate
3
OC ^ -adrenoceptors which leads to a greater inhibition of [ H]NA
release. This can be depicted diagrammatically as shown in Figure
53. Receptor binding studies showed that the density of
P-adrenoceptors in rat cerebral cortex is about 50fmol/mg protein
(Dibner et al., 1979).
Unlike O.C. tissue chops, Ueda et al. (1983) demonstrates that
the release of endogenous NA in the hypothalamus may be regulated via
presynaptic as well as p^ and p^-adrenoceptors. Thus, they
found that not only yohimbine but also isoprenaline enhanced electrical
stimulation (2HZ) of endogenous NA release. In contrast, the
^-adrenergic antagonist, prazosin only weakly enhanced NA release.
Furthermore, the stimulation of release by p-adrenergic agonist,
isoprenaline is antagonised by the {^-adrenergic antagonist, atenolol
and the p^-adrenergic antagonist, butoxamine. These studies of Ueda
et al. (1983) suggest the a role for p^ and p^-adrenoceptors in
3
the regulation of [ H]NA release.
It is generally accepted that during depolarization, adenosine 
(Kuroda, Y. and Mcllwain, H., 1979; Fredholm and Hedqvist, 1980) and 
ATP, ADP and AMP (Mcllwain, 1977; Burnstock, 1981) released from the
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nerve terminals might themselves function as neurotransmitters and cause 
presynaptic inhibition or regulate the release of other neurotransmitter 
systems such as noradrenaline (Harms et al., 1979; Jonzon and 
Fredholm, 1984; Allgaier et al., 1987), dopamine (Harms et al., 1979; 
Javis and Williams, 1987) and acetylcholine (Pedata et al., 1983; 
Corradetti et al., 1984).
The present study demonstrates that the adenosine A^ agonist,
CHA (Fredholm and Dunwiddie, 1988) inhibited the 20mM K -stimulated 
3
release of [ H]NA more potently than adenosine (Fig. 26) from the O.C.
+
tissue chops. Additionally, adenosine inhibition of K -stimulated 
release is reversed by IBMX (Fig. 27) but not by the PDE-inhibitor RO 
20-1724 (Fig. 28) suggesting that IBMX acts as an adenosine antagonist
as well as a PDE inhibitor. Furthermore, the fact that IBMX is able to
+ 3
further enhance the K -stimulated release of [ H]NA in the presence
- 6
of 10 M adenosine by 20% (Fig. 27) suggests the possible involvement
+
of released endogenous adenosine in the regulation of K stimulation 
3
of [ H]NA release. The above findings are in agreement with those
reported by other researchers which show that adenosine and ATP
3
inhibition of depolarization stimulated release of [ H]NA can be 
antagonised by methylxanthines including theophylline, IBMX and caffeine 
(Phillis et al., 1979; Fredholm, 1980).
This view is supported by the observation that the selective 
adenosine A^ antagonist, CPDPX (Martison et al., 1987) not only more
potently reverses the adenosine inhibitory effect, but at concentrations
-5 +
greater than 10 M further enhances the 20mM K stimulated release
3
of [ H]NA by 10% (Fig. 29). However, the finding that IBMX which
+
reverses the adenosine inhibition of 20mM K -stimulated release of 
3
[ H]NA does not reverse the C^-adrenergic agonist, NA inhibition of
+ 3
20mM K -stimulated release of [ H]NA (Fig. 30) suggests that
O
endogenous adenosine does inhibition [ H]NA release.
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4.3 The possible role of cAMP in mediating the (X^-adrenergic
regulation of NA release
a^-Adrenoceptors have been shown to inhibit cAMP formation
in adipocytes (Aktories et al., 1980; Burns et al., 1982), neuronal
cell NG 108/15 (Sabol and Nirenberg, 1979; Kahn et al., 1982),
platelets (Jakobs et al., 1976) and rat pancreatic islets (Yamazaki et
al., 1982). In view of this, a likely mechanism for a^-adrenergic
agonist inhibition of NA release is that it is mediated by decreasing
cAMP levels. However, G protein linked to the inhibition of voltage 
2+
sensitive Ca channels and Gv protein linked to the regulation ofI\
+
K channels have recently been described (Sasaki and Sato, 1987;
Logothetis et al., 1987) Allagier et al. (1985) demonstrated that
pretreatment of rabbit hippocampus brain slices with pertussis toxin
(IAP) which ADP-riboxylates the G-protein of the cell membrane or
N-ethylmaleimide (NEM) (Allagier et al., 1986) which inactivates
G-protein reduces the effect of both a^-adrenergic agonist, clonidine
and (x^-adrenergic antagonist, phentolamine response on the electrical
3
stimulated release of [ H ]NA. Thr.s - raises the possible role of cAMP 
in the regulation of NA release. Thus, the present study sought to 
provide evidence for a role of cAMP by studying the effect of (a) 
conditions that increase cAMP i.e. of cAMP analogue db-cAMP, 
PDE-inhibitors to prevent the catabolism of cAMP or by direct activation 
of the catalytic unit of adenylate cyclase by forskolin on 
a^adrenergic inhibition of NA release and (b) a comparison between the 
conditions under which a 2_adrenergic agonists inhibit NA release and 
cAMP formation. Thus, if a 2“a^rener9^c agonists inhibit NA release 
by inhibiting cAMP formation, then a correlation between these two 
actions of oc^adrenergic agonists would be predicted.
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4.3.1 Influence of cAMP on OC^-adrenoceptors regulated release of 
3
[ H]NA from O.C. and hypothalamic tissue chops
The present study shows that forskolin, db-cAMP and IBMX enhance
+ 3
the 20mM K -stimulated release of [ H]NA from O.C. tissue chops by
20.8%, 29.0% and 19.0% respectively (Table 5) but had no effect on the
3
basal release of [ H]NA. In addition, when forskolin or db-cAMP is
3 +
combined with IBMX, the release of [ H]NA stimulated by 20mM K is
further increased by 10% (Table 6). Similarly, in hypothalamic tissue
chops, dbcAMP or forskolin when combined with IBMX enhance the 25mM but
+ 3
not the 30mM K -stimulated release of [ H]NA by 25.5% and 23.6%
respectively (Table 8A and B). This suggests that cAMP may be involved
3
in the regulation of depolarization-evoked release of [ H]NA from rat
O.C. and hypothalamic tissue chops. These results are in agreement
with the finding that substances which increase intracellular cAMP
formation such as cAMP analogues including db-cAMP and 8-Br-cAMP as well
as PDE-inhibitors including IBMX, 7-benzyl-IBMX, ZK 62771 and
RO 20-1724, or forskolin enchanced the electrical-stimulated release of 
3
[ H]NA from rat brain slices (Markstein et al., 1984; Schoffelmeer
et al., 1985, 1986) and synaptosomes (Schoffelmeer et al., 1985). On
+ 3
the contrary, veratrine or 13mM K -induced release of [ H]NA from
rat neocortical slices, is enhanced only by cAMP analogues and forskolin
while PDE inhibitors including IBMX, ZK 62771 and RO 20-1724 inhibited
3
the stimulated release of [ H]NA (Schoffelmeer and Mulder, 1983b).
The difference between the effect of PDE inhibitors on
+ ’ 3
electrical stimulation and K or veratrine-induced release of [ H]NA
may be related to the differences in the degree of stimulation. An
+
alternative explanation for the effect of IBMX on K -stimulated 
3
release of [ H]NA between the present study and that of Schoffelmeer
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et al. (1985), is that IBMX may penetrate better into the neocortical 
rat brain slices used in the study of Schoffelmeer et al. (1985) 
compared to the cortical brain slices obtained from adult rats used in
the present study. In support of this although IBMX inhibited the 13mM
+ 3
K -stimulated release of [ H]NA, theophylline, an adenosine
antagonist, which does not normally appreciably penetrate cell membranes
3
enhances the stimulated release of [ H]NA (Schoffelmeer et al.,
1985). The present study suggests that IBMX enhances the 20mM
+ 3
K -stimulated release of [ H]NA by acting as an adenosine
antagonist. Furthermore, in agreement with the findings of Schoffelmeer 
et al. (1983b), RO 20-1724 which inhibits cAMP-PDE selectively (Daly,
1977) but does not act as adenosine antagonist, is found to inhibit the
+ 3
K -stimulated release of [ H]NA by about 20% (Table 7). The result
+
suggests that RO 20-1724 may affect the K -stimulated release of 
3
[ H]NA possibly via other unknown release mechanisms.
+
If OC ^ -adrenergic agonists inhibit the K -stimulated 
3
release of [ H]NA by decreasing the intracellular cAMP formation, it 
would then be anticipated that the increase in intracellular cAMP by 
db-cAMP or forskolin could counteract the inhibitory effect of the
agonist. However, the present study demonstrates that a^-^renergic
+ 3
agonist inhibition of 20mM K -stimulated release of [ H]NA from O.C.
tissue chops is partially reversed by db-cAMP either in the absence 
(Table 5) or presence (Table 6) of IBMX, but unexpectedly, not by 
forskolin either in the absence (Table 5) or presence (Table 6) of
IBMX. In hypothalamic tissue chops c^-a^renergic agonist
+ 3
inhibition of 25mM K -stimulated release of I H]NA is not reversed
by either db-cAMP (Fig. 8) or forskolin (Fig. 8) combined with IBMX
suggesting that unlike O.C. tissue chops changes in intracellular cAMP
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levels by db-cAMP do not affect the a 2_a(3renergic agonist inhibitory
+ 3
effect on the 25mM K -stimulated release of [ H]NA from hypothalamic
tissue chops.
Rabe et al. (1982) demonstrate that unstimulated release of
3
[ H]NA from clonal pheochromocytoma cell line, PC 12 is not affected
by any concentration of forskolin. However, forskolin up to 10/iM
+
concentration is able to enhance the 50mM K -stimulated release of
3 -4
[ H]NA, while higher concentration (10 M) of forskolin tends to
3
inhibit [ H]NA release. Their results thus suggest a modulatory role 
3
of forskolin on [ H]NA release. This may provide an explanation for
the failure of forskolin to reverse the a^-adrenergic agonists
+ 3
inhibition of K -stimulated release of [ H]NA observed in the
present study.
+
The inhibition of (X^-adrenergic agonists on K stimulated 
3
release of [ H]NA from O.C. tissue chops is very rapid (Figs. 17,
18). The fact that a minimum incubation period of 30 minutes with very
-3
high concentration of db-cAMP (10 M) is required to partially reverse
+
the CX^-adrenergic agonists inhibition of K -stimulated release of 
3
[ H]NA suggest that other mechanisms may be involved (Table 5).
Electrophysiological studies show that neurotransmitters including NA,
+ +
5-HT and GABA which do not have any effect on Na and K
2+
voltage-sensitive channels, inhibits the voltage sensitive Ca
channels in chick sensory neurons (Dunlap and Fishback, 1981).
Furthermore, db-cAMP has been shown to cause a prolonged
hyperpolarization of neuronal membranes, and hence a prolongation of 
2+
Ca influx, thereby preventing the inhibitory effect of these
2+
neurotransmitters on voltage sensitive Ca channels (Reuter, 1983).
This may be an alternative suggestion for the present study to explain
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why db-cAMP was able to partially reverse the C^-adrenergic agonists
+ 3
inhibitory effect on K -stimulated release of [ H]NA from the O.C.
tissue chops but not forskolin. One interpretation of the data
obtained in the present study is that Ct^-adrenergic agonists may
+ 3
inhibit the K -stimulated release of [ H]NA via G-protein linked to
2+
voltage sensitive Ca channels.
4.3.2 Stimulation of cAMP formation
4.3.2.1 Stimulation of p -adrenergic agonist isoprenaline, a  and 
B -adrenergic agonist, NA and adenosine
The present study demonstrates that isoprenaline stimulated cAMP 
formation 1.5 fold (Fig. 31), whereas NA stimulated cAMP formation about 
3.0 fold (Fig. 31). Furthermore, isoprenaline stimulation of cAMP 
formation is potentiated by a^-adrenergic agonist, phenylephrine 
(Fig. 50) but not by (^-adrenergic antagonist, UK 14304-18 (Fig. 50). 
This is in agreement with the findings of Etgen et al. (1987) who also 
show that isoprenaline stimulation of cAMP formation is enhanced by 
phenylephrine but not clonidine. Thus, the results suggest that the 
greater stimulation of cAMP formation observed with NA compared with 
isoprenaline is due to the synergistic effect of and p -adrenergic 
agonist.
From the present study, NA stimulation of cAMP formation is not
affected by phenylephrine (Fig. 49) but is inhibited by a^-adrenergic
agonists in a biphasic manner with the following order of potency
-9
(ICp-Q values in parenthesis) UK 14304-18 (6 x 10 M ) clonidine
-8 -7
(10 M) >  BHT-920 (5 x 10 M). This suggests that there could be
two subclasses of a^-adrenoceptors blocking the response of 
NA-stimulation of cAMP formation.
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NA stimulation of cAMP formation is more potently blocked by 
a^-adrenergic antagonist, prazosin than o^-adrenergic antagonist, 
yohimbine and p-adrenergic antagonist, propranolol (Fig. 34). The 
result is supported by the findings of Perkin and Moore (1973), Davis 
et al. (1978), Daly et al. (1980) and Johnson and Minneman (1986) who 
also reported that a^-adrenergic antagonist is more potent than 
a^-adrenergic antagonist at inhibiting the NA stimulation of cAMP 
formation in rat brain slices. Thus, the failure of a^-sdrenergic 
antagonist to enhance the NA stimulation of cAMP formation argues against 
the involvement of a^-adrenoceptors in NA stimulatory effect of cAMP 
formation. This further confirms the present suggestion that NA 
stimulation is due to the synergistic effect of and p-adrenergic 
agonist.
Evidence of a potentiation of p -stimulation by 
a^-adrenoceptor is also observed in membrane particulate fractions 
prepared from guinea pig cortex (Daly et al., 1980). In contrast, 
cultures of astrocytes isolated from perinatal mouse brain (Van Calker 
et al ., 1978; 1979) or rat cerebral cortical tissue (McCarty and De
Vellis, 1978) do not show augmentation of p-adrenergic agonist 
stimulation of cAMP formation since a greater increase in cAMP formation 
is observed with isoprenaline alone. Furthermore, isoprenaline 
stimulation of cAMP formation is inhibited by NA, and the effect of 
which can be reversed by Ct^-adrenergic antagonists such as 
phentolamine and phenoxybenzamine (Van Calker et al., 1978). In 
addition, NA stimulation of cAMP formation can be further enhanced by 
phentolamine (McCarthy and De Vellic, 1978). Unlike brain slices, 
these results suggest a^-adrenoceptors in astrocytes cultures are 
linked to the adenylate cyclase.
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In contrast, Pile and Enna (1986) reported that isoprenaline 
stimulation of cAMP formation is not potentiated by phenylephrine but by 
UK 14304-18. Furthermore, they reported that isoprenaline and 
a  -adrenergic agonist (6-fluoronorepinephrine) stimulation of cAMP 
formation is more potently blocked by yohimbine than by prazosin. The 
inhibitor results of the present study taken together with those of 
other researchers (Perkin and Moore, 1973; Davis et al., 1978; Daly 
et al., 1980; Daly et al., 1981; Johnson and Minnemari, 1986; Etgen 
et al., 1987) do not support the results obtained by Pile and Enna,
(1986) which suggest that NA stimulation of cAMP formation is due to the 
synergistic effect of {3 and a^-adrenergic agonist.
Since cAMP formation in brain slices may continuously be
catabolised by PDE, the effect of PDE on isoprenaline and NA stimulation
of cAMP formation were examined with PDE inhibitors IBMX (Well and
Kramer, 1981) and RO 20-1724 (Schwabe et al., 1978). The results show
that surprisingly IBMX inhibited the isoprenaline and NA (Fig. 32)
stimulation of cAMP formation, whereas RO 20-1724 although raising the
basal level of cAMP did not alter either the EC values i.e. 4 x
50
-6 -9
10 M and 55 x 10 M or the overall stimulation i.e. 1.5 fold and 3
fold of cAMP formation stimulated by isoprenaline and NA respectively 
(Fig. 33). Since IBMX can act as a potent adenosine antagonists 
(Stiles, 1986), the abolition by IBMX of NA and isoprenaline stimulation 
of cAMP formation suggests that endogenous adenosine potentiates the 
action of p -adrenergic agonist on cAMP formation in rat brain slices. 
The above observations are in agreement with Daly et al. (1980) who show- 
that NA, isoprenaline, histamine, dopamine, serotonin and adenosine 
stimulation of cAMP formation in guinea pig cerebral cortex particulate 
preparation is inhibited by adenosine antagonists, theophylline and
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IBMX, but not potentiated by PDE inhibitor ZK 62771. Furthermore, Daly
et al. (1980) in rat cerebral cortical slices also found that adenosine
is necessary for a a-response.
In the present study, IBMX inhibited adenosine stimulation of
cAMP formation, causing a shift to the right of adenosine concentration
curve (Fig. 16), while RO 20-1724, although raising the basal level of
-5
cAMP formation does not affect the EC-.- value (6 x 10 M) of
DU
adenosine (Fig. 36). Indeed, NA stimulation of cAMP formation is 
further potentiated by 0.9 fold in the presence of adenosine (Fig. 37). 
This agrees with the hypothesis that adenosine potentiates NA effects in 
rat brain.
Interestingly when NA stimulation of cAMP formation is 
potentiated by adenosine, adrenergic antagonists have a different order 
of potency and efficacy (Fig. 38) when compared with their action of NA
stimulation along (Fig. 34). Thus values in parenthesis)
-9 -9
yohimbine (8 x 10 M ) >  prazosin (2.5 x 10 M) >  propranolol (6 x
“ 7 % .10 M) and inhibited cAMP formation by 40%, 30% and 22% respectively 
-5
at 10 M concentration (Fig. 38). This suggests that yohimbine is 
the most effective and potent at inhibiting the adenosine combined with 
NA stimulation of cAMP formation. This is supported by the findings of 
Schultz and Kleefeld (1979) who show that adenosine combined with NA 
stimulation of cAMP formation is inhibited more by phentolamine than by 
propranolol. In addition, the present study also demonstrates that 
adenosine stimulation of cAMP formation is potentiated by UK 14304-18 
(Fig. 51). On the contrary, in the absence of adenosine, NA 
stimulation of cAMP formation is most effectively blocked by 
propranolol. Thus, the results suggest that adenosine potentiates NA 
stimulation of cAMP formation by modulating the cell surface receptors.
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4.3.2.2 Stimulation of cAMP formation by forskolin
Forskolin which is known to increase cAMP formation by directly
activating the catalytic unit of the adenylate cyclase (Seamon and Daly,
1981, 1983; Daly et al., 1982; Bender et al., 1984) stimulated cAMP
formation in a concentration-dependent manner (Fig. 31) with e c 5q 
-6
value of 5 x 10 M and a maximum stimulation of 6 to 8 fold cAMP
-4
formation achieved at 10 M either alone or in the presence of PDE 
inhibitors including IBMX (Fig. 32) and RO 20-1724 (Fig. 33).
Therefore this suggests that in brain slices PDE activity is low 
compared to cell culture where PDE-inhibitors are found to enhance cAMP 
formation (Van Calker et al., 1978; Wojcik and Neff, 1984). In
addition, from the above study, it can be concluded that failure of
+ 3
Ct^-adrenergic agonist to inhibit the K -stimulation of [ H]NA
release could not be due to the failure of forskolin to stimulate cAMP 
formation in the O.C. tissue chops used in the present study, since 
there are considerable increased in cAMP formation with the concentrations
of forskolin used to try and reverse a^-adrenergic inhibition.
- 6 - 6  
Forskolin (10 M and 5 x 10 M) which itself stimulated cAMP
formation, is only able to increase NA, isoprenaline and adenosine
stimulation of cAMP formation in an additive manner (Fig. 39). On the
-7
contrary, at submicromolar concentration (10 M), forskolin, which
itself does not have any effect on cAMP formation potentiated NA
-5 -6 -4
(10 M), isoprenaline (10 M) and adenosine (10 M) stimulation of
cAMP formation by 0.7, 0.9 and 1.5 fold respectively (Fig. 39).
-6
Forskolin (10 M) has also been shown to potentiate cAMP formation by 
histamine, serotonin, NA, isoprenaline, adenosine, prostaglandin E2 and 
vasoactive intestinal peptide in rat and guinea pig cerebral cortical 
slices as well as in rat striatal slices (Daly et al., 1982; Seamon and
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Daly, 1983). It has been proposed that at low concentration, forskolin 
acts synergistically with the high affinity sites of Gs , which then 
potentiate the receptors effect on cAMP formation (Daly et al., 1982; 
Seamon and Day, 1983; Seamon and Wetzel, 1984; Barovsky et al., 1984, 
1985).
Forskolin stimulation of cAMP formation in human adipocytes 
(Burns et al., 1982, 1987), human platelets (Insel et al., 1982) and in 
rat cerebral cortical membranes(Kitamura et al., 1985) have been shown 
to be inhibited by oc^-adrenergic agonists such as clonidine, NA and 
adrenaline. Furthermore, using rat neonatal cerebral cortical slices, 
Duman and Enna, (1986) reported that a 2~a^rener9ic agonists including
6-fluoronorepinephrine, clonidine and UK 14304 inhibited forskolin 
stimulation of cAMP formation in a concentration dependent manner, 
while ^-adrenergic agonist, phenylephrine slightly potentiated the 
forskolin response. Thus all the above findings suggest that 
CX^-adrenergic agonist is directly linked to Gi and thus to the 
catalytic unit of adenylate cyclase.
In contrast, the present study found that the c^-adrenergic 
agonist, clonidine (Fig. 47) and UK 14304-18 (Fig. 46) were unable to 
inhibit forskolin stimulation of cAMP formation in O.C. rat brain 
slices. This is a surprising observation in view of reports that (a) 
forskolin stimulation is inhibited by a 2-adrenergic agonist and (b) 
there are plenty of a^-adrenoceptors in cortex (Rouot et al., 1980; 
Loftus et al., 1984; Boyajian et al., 1987; Boyajian and Leslie,
1987). This suggests that not all a^-adrenergic receptors are 
linked to adenylate cyclase via Gi.
4.3.2. 3 Effect of depolarizing agents on cAMP formation
Electrical stimulation (Kakinchi et al., 1968a, b; Zanella and 
+
Rail, 1973), K depolarisation (Shimiju and Daly, 1972) as well as
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other depolarizing agents including batrochotoxin, veratine and ouabain 
(Shimizu et al., 1970) have been shown to stimulate cAMP formation in 
rat brain slices.
+
The present study demonstrates that K depolarization (40 -
80mM) stimulated cAMP formation maximally between 2.2 and 2.5 fold
+
(Fig. 40) in rat O.C. tissue chops. High K concentrations
(100-140mM) decreases cAMP formation (Fig. 40) possibly due to influx of 
2+
Ca which activates the calcium/calmodulin dependent PDE (Hemmings 
et al., 1986).
+
In contrast, in guinea pig cerebral cortex slices, K
depolarization (140mM) stimulated cAMP formation by 48 fold, while
+ + 
maximum K stimulation (150mM) in the absence of Na only slightly
+
reduced the K response (Shimizu et al., 1972). This could simply be
2+
due to the difference of Ca sensitivity of PDE between different
+
animal slices. In addition, K , batrochotoxin, ouabain, veratine
2+
stimulation of cAMP formation are dependent on Ca (Shimizu et al.,
1970; Zanella et al., 1973; Ferrendelli et al., 1976; Schwabe
2+
et al., 1978). An alternative explanation is that low Ca activates 
2+
while high Ca inhibit adenylate cyclase activity (Brostrom et al., 
1977).
-6
Forskolin (10 M) stimulated cAMP formation by 6 fold under
+ + 
non depolarizing (5mM K ) and mild depolarizingf (20mM K )
+
conditions (Fig. 43). However, when combined with 40mM and 60mM K ,
its response on cAMP formation is reduced to 50% and 100% respectively
2+
(Fig. 43). This suggests that the influx of Ca during 
depolarization may activate the calcium/calmodulin dependent PDE 
(Hemmings et al., 1986), thereby leading to a decrease in cAMP
-3 %
formation. This is confirmed by the finding that RO 20-1724 (10 M)
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completely reverses the effect of forskolin combined with 40mM K+ 
stimulation of cAMP formation (Fig. 44).
Cocaine, a potent NA uptake inhibitor (Carmichael and Israel,
+
1973) has been shown to inhibit K , ouabain, veratine, NA, histamine
and adenosine stimulation of cAMP formation (Shimizu et al., 1972).
3
Since DMI, which is used as NA uptake inhibitor in the study of [ H]NA
+
release, its effect on K stimulation of cAMP formation in the O.C.
tissue chops is examined. The present study demonstrates that 20mM and 
+
40mM K stimulation of cAMP formation is not affected by DMI (luM)
(Fig. 42).
The present study demonstrates that UK 14304-18 does not inhibit
+
the K stimulation of cAMP formation either alone or in the presence
of RO 20-1724 (Fig. 41). Since depolarization is mainly due to the
neuronal event rather than glial, and the proportion of neurons to glia
population is not determined, it may therefore be difficult to pick up a
small a^-effect situated on the nerve terminals during 
+
K -stimulation of cAMP formation.
In conclusion, the findings that activation of
CC^-adrenoceptors by ct^-adrenergic agonist leads to large
+ 3
inhibition of K -stimulated release of [ H]NA, and the failure of
+
the agonist to inhibit K -stimulation of cAMP formation under parallel
experimental conditions suggests that there is little correlation
3
between cAMP inhibition and C^-adrenergic inhibition on [ H]NA 
release.
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+ve -ve
Figure 53 Schematic representation of presynaptic autoinhibition
CX^-Adrenoceptors acted upon by NA in the presence of 
J3-adrenergic antagonist, propranolol on the noradrenergic 
nerve terminals in the CNS.
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5 CONCLUSION
The ability of forskolin and db-cAMP to enhance
+ 3
K -stimulated release of [ H]NA suggests a role for cAMP in
synaptic transmission. There is no evidence that CX^-adrenergic
+ 3
agonists inhibit K -stimulated release of [ H]NA by inhibiting
cAMP formation, since forskolin does not reverse the CX^-adrenergic
inhibitory effect. OC ^ -Adrenergic agonist inhibition of
+ 3
K -stimulated release of [ H]NA is very rapid. However, the fact
that db-cAMP is only able to partially reverse the (X^-adrenergic
agonist inhibitory effect over a period of 30 minutes incubation at a
high concentration suggests that other mechanisms may be involved.
Furthermore, the failure of a^-adrenergic agonists to inhibit
+
forskolin, isoprenaline, adenosine and K stimulation of cAMP 
formation under parallel experimental conditions indicates that there
is no correlation between cAMP and CC^-adrenergic agonists
3
inhibitory effect on [ H]NA release. In contrast, CX^-adrenergic
agonists are found to inhibit the NA stimulation of cAMP formation in
a biphasic manner. This suggests that different pools of
a^-sdrenoceptors are present. However, the fact that
O^-adrenergic antagonists do not enhance the NA stimulation of cAMP
formation suggests that different mechanisms may be involved.
My results however support the increasing evidence in the
literature which suggests that OC ^ -adrenoceptors may be directly
2+
linked to voltage-sensitive Ca channels via G-proteins, since
3
OC2“a{3renergic inhibitory effects on [ H ]NA release can only be 
observed during depolarization.
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